{"ticker": {"uuid": "31f31298-a544-49e1-8ab7-d3caae9549ed", "symbol": "TAK", "name": "Takeda Pharmaceutical Co Ltd ADR", "exchange": "NYSE", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "charts": {"tiers": [{"count": 39, "label": "Direct company coverage"}, {"count": 0, "label": "Industry context"}, {"count": 0, "label": "Sector context"}], "events": [{"count": 18, "label": "Market update"}, {"count": 11, "label": "Earnings"}, {"count": 5, "label": "Regulatory and legal"}, {"count": 4, "label": "Deals and strategy"}, {"count": 1, "label": "Analyst action"}], "sources": [{"label": "Business Wire", "count": 4}, {"label": "MT Newswires", "count": 4}, {"label": "DirectorsTalk Interviews", "count": 2}, {"label": "scanx.trade", "count": 2}, {"label": "Market source", "count": 2}, {"label": "Benzinga", "count": 2}, {"label": "MarketBeat", "count": 2}, {"label": "BioPharma Dive", "count": 2}]}, "insights": [{"text": "Early balanced news score", "tone": "neutral", "label": "Weighted tone", "value": "54/100"}, {"text": "2.69 effective stories after overlap and weighting.", "tone": "neutral", "label": "Evidence confidence", "value": "27/100"}, {"text": "Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.", "tone": "neutral", "label": "Market reaction", "value": "Early company-news score"}, {"text": "76/100 evidence concentration around this catalyst.", "tone": "neutral", "label": "Primary event", "value": "Market update"}, {"text": "97% of weighted evidence is company-specific.", "tone": "positive", "label": "Company focus", "value": "39"}, {"text": "lower dispersion means the independent stories agree more closely.", "tone": "positive", "label": "Evidence agreement", "value": "12/100"}, {"text": "+3.6% over one week, +4.0% over four weeks, trend active, and materially above fair value.", "tone": "positive", "label": "Trend context", "value": "Trend active"}, {"text": "Climate-ready healthcare: Our 2026 global CSR programs", "tone": "neutral", "label": "Latest direct headline", "value": "Neutral"}], "classifier": {"events": [{"count": 18, "event": "general", "label": "Market update", "weight": 11.44}, {"count": 11, "event": "earnings", "label": "Earnings", "weight": 7.1}, {"count": 5, "event": "regulatory", "label": "Regulatory and legal", "weight": 3.1}, {"count": 4, "event": "deals", "label": "Deals and strategy", "weight": 2.4}, {"count": 1, "event": "analyst", "label": "Analyst action", "weight": 0.6}], "pipeline": {"status": "healthy", "providers_attempted": 4, "providers_with_results": 4, "raw_articles": 149, "unique_stories": 88, "duplicates_removed": 61, "relevant_stories": 39, "matched_archive_stories": 58, "current_evidence": 12, "direct_evidence": 39, "archive_articles": 13, "durable_story_count": 36, "durable_evidence_used": true, "durable_collected_at": "2026-09-24T19:55:26.399342+00:00"}, "confidence": 76, "primary_event": "general", "primary_label": "Market update", "negative_events": 2, "positive_events": 10}, "updated_at": "2026-09-25T11:26:44.805560+00:00", "total_unique": 39, "total_fetched": 39, "interpretation": {"tone": "neutral", "label": "Early company-news score", "risks": [], "badges": ["Provisional evidence"], "summary": "Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.", "confidence": 27, "event_label": "Market update", "opportunities": [], "classification": "provisional", "sentiment_word": "balanced"}, "market_context": {"trend_tone": "positive", "latest_week": "2026-09-18", "trend_label": "Trend active", "latest_close": 18.91, "trend_signal": "1", "one_week_move": 3.6, "reaction_tone": "positive", "fair_value_gap": 31.0, "four_week_move": 4.0, "reaction_label": "Price confirming higher", "fair_value_tone": "negative", "market_dynamics": 0.690486, "market_sentence": "+3.6% over one week, +4.0% over four weeks, trend active, and materially above fair value.", "fair_value_label": "Materially above fair value", "twelve_week_move": 18.9, "relative_strength": 6.248972, "has_market_context": true, "expectation_direction": "undecided", "expectation_probability": 47.4205, "market_dynamics_buy_signal": false}, "total_relevant": 39, "pipeline_health": {"status": "healthy", "providers_attempted": 4, "providers_with_results": 4, "raw_articles": 149, "unique_stories": 88, "duplicates_removed": 61, "relevant_stories": 39, "matched_archive_stories": 58, "current_evidence": 12, "direct_evidence": 39, "archive_articles": 13, "durable_story_count": 39, "durable_evidence_used": true, "durable_collected_at": "2026-09-25T11:26:44.805560+00:00"}, "sentiment_summary": {"tone": "neutral", "label": "Early balanced news score", "score": 54, "total": 39, "neutral": 27, "negative": 2, "positive": 10, "raw_score": 67, "confidence": 27, "dispersion": 12, "story_count": 39, "window_days": 30, "direct_share": 97, "source_count": 11, "score_version": "evidence-v10", "evidence_count": 12, "evidence_status": "provisional", "information_mass": 0.309, "weighting_method": "event-aware exponential freshness decay", "newest_article_at": "2026-09-24T09:47:40+00:00", "direct_story_count": 39, "effective_articles": 2.69, "sector_story_count": 0, "direct_source_count": 11, "industry_story_count": 0, "source_concentration": 0.3726, "directional_story_count": 12}, "articles": [{"url": "https://www.takeda.com/our-impact/our-stories/climate-ready-healthcare-global-csr-programs", "tier": "direct", "title": "Climate-ready healthcare: Our 2026 global CSR programs", "topics": ["Life Sciences", "Economy Macro"], "summary": "Takeda announced its 2026 global Corporate Social Responsibility (CSR) programs, committing USD 22.2 million to four new multi-year projects aimed at strengthening climate-resilient health systems worldwide. These initiatives, chosen by Takeda employees, will support organizations like Corus International, Humanity & Inclusion \u2013 Handicap International, Kwame Nkrumah University of Science and Technology, and Terre des hommes Foundation in countries such as Nepal, Honduras, Peru, Ghana, Egypt, and Lebanon. The programs focus on areas including early warning systems, resilient service delivery, workforce capacity building, and greener practices to address the widespread impact of climate change on global health outcomes.", "age_days": 1.1, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.takeda.com/our-impact/our-stories/climate-ready-healthcare-global-csr-programs", "source_name": "Takeda Pharmaceuticals", "published_at": "2026-09-24T09:47:40", "tone_signals": ["Negative financial language"], "company_focus": 0.86, "freshness_pct": 69.0, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.041109, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 86, "evidence_strength": 0, "published_display": "24 Sep 2026 09:47", "direction_included": false, "company_focus_label": "Company discussed", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://ca.finance.yahoo.com/quote/4502.T", "tier": "direct", "title": "Takeda Pharmaceutical Company Limited (4502.T) Stock Price, News, Quote & History", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "This article provides comprehensive financial data for Takeda Pharmaceutical Company Limited (4502.T), including its current stock price, dividend information, key financial metrics, performance overview, and analyst insights. The company recently announced a cash dividend and has shown significant year-to-date and annual returns. Takeda operates in the pharmaceutical industry, focusing on gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience.", "age_days": 2.1, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://ca.finance.yahoo.com/quote/4502.T", "source_name": "Yahoo! Finance Canada", "published_at": "2026-09-23T09:47:40", "tone_signals": ["Capital returned"], "company_focus": 1.0, "freshness_pct": 75.1, "sentiment_pct": 55, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 4, "evidence_weight": 0.109182, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "23 Sep 2026 09:47", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.reuters.com/legal/litigation/roche-proposes-former-takeda-ceo-board-seat-2026-09-23", "tier": "direct", "title": "Roche proposes former Takeda CEO for board seat", "topics": ["Life Sciences"], "summary": "Roche announced its proposal to elect Christophe Weber, the former CEO of Takeda Pharmaceuticals, to its board of directors at its upcoming Annual General Meeting in March. Roche Chairman Severin Schwan stated that Weber's extensive knowledge of the healthcare industry and leadership experience would significantly strengthen the board. This move signals Roche's intention to enhance its leadership with seasoned pharmaceutical expertise.", "age_days": 2.3, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "editorial_wire", "source_link": "https://www.reuters.com/legal/litigation/roche-proposes-former-takeda-ceo-board-seat-2026-09-23", "source_name": "Reuters", "published_at": "2026-09-23T05:12:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 45.7, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.038868, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "23 Sep 2026 05:12", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.asahi.com/ajw/articles/16813325", "tier": "direct", "title": "Takeda\u2019s new president aims to increase line of drug candidates", "topics": ["Earnings", "Life Sciences", "Mergers And Acquisitions"], "summary": "Julie Kim, the new president of Takeda Pharmaceutical Co., is focused on accelerating drug development through the integration of AI and new technologies. She aims to establish Takeda as a world leader in its priority fields by strengthening its drug pipeline, including three new medicines slated for release within the next year. Kim, the company's first female president, emphasizes the importance of a robust line of potential drug candidates for long-term growth, building on the globalization efforts initiated by her predecessor, Christophe Weber.", "age_days": 2.6, "is_stale": false, "sentiment": "neutral", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "publisher", "source_link": "https://www.asahi.com/ajw/articles/16813325", "source_name": "\u671d\u65e5\u65b0\u805e", "published_at": "2026-09-22T21:53:56", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 77.6, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.067024, "influence_label": "None", "event_confidence": 93, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "22 Sep 2026 21:53", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.ad-hoc-news.de/boerse/news/nebenwerte/takeda-pharmaceutical-stock-holds-at-usd-18-91-as-pipeline-advances/70156878", "tier": "direct", "title": "Takeda Pharmaceutical stock holds at USD 18.91 as pipeline advances", "topics": ["Financial Markets", "Life Sciences"], "summary": "Takeda Pharmaceutical's stock closed at USD 18.91 on September 21, 2026, maintaining its position as the company advanced its oncology pipeline. Recent data, including Phase 3 research for arcotatug tavatecan, were presented at the ESMO 2026 congress. Despite a consensus Buy rating from analysts, there is no published consensus price target, focusing investor attention on clinical progress rather than immediate financial forecasts.", "age_days": 2.8, "is_stale": false, "sentiment": "positive", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.ad-hoc-news.de/boerse/news/nebenwerte/takeda-pharmaceutical-stock-holds-at-usd-18-91-as-pipeline-advances/70156878", "source_name": "AD HOC NEWS", "published_at": "2026-09-22T16:54:00", "tone_signals": ["Buy Rating"], "company_focus": 1.0, "freshness_pct": 38.3, "sentiment_pct": 57, "evidence_basis": "archived_article", "evidence_share": 12.6, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.038794, "influence_label": "Medium", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 39, "published_display": "22 Sep 2026 16:54", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "12.6"}, {"url": "https://finance.yahoo.com/healthcare/articles/takeda-highlights-stage-oncology-pipeline-133000609.html", "tier": "direct", "title": "Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026", "topics": ["Clinical Trials", "Esmo", "Gastric Cancer", "Lung Cancer", "Oncology"], "summary": "Late-Breaking Abstract to Feature New Data from First Phase 3 Registrational Study of Arcotatug Tavatecan in Previously Treated Advanced Gastric Cancer TAK-928 Presentations Reinforce Potential in Patients with Immunotherapy-Resistant Non-Small Cell Lung Cancer (NSCLC) and Previously Untreated NSCLC Takeda Continues to Progress Clinical Development of Arcotatug Tavatecan and TAK-928; New Non-Squamous NSCLC Sub-Trial Added to Global Phase 3 MarsLight-11 Study Evaluating TAK-928 vs. Docetaxel Monotherapy OSAKA, Japan & CAMBRIDGE, Mass., September 22, 2026--(BUSINESS WIRE)--Takeda(TSE:4502/NYSE:T", "age_days": 2.9, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "press_release", "source_link": "https://finance.yahoo.com/healthcare/articles/takeda-highlights-stage-oncology-pipeline-133000609.html", "source_name": "Business Wire", "published_at": "2026-09-22T13:30:00+00:00", "tone_signals": [], "company_focus": 0.78, "freshness_pct": 36.4, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "evidence_weight": 0.016923, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 78, "evidence_strength": 0, "published_display": "22 Sep 2026 13:30", "direction_included": false, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.directorstalkinterviews.com/takeda-pharmaceutical-company-l-tak-stock-analysis-exploring-a-17-6-potential-upside-and-strong-revenue-growth/4121263186", "tier": "direct", "title": "Takeda Pharmaceutical Company L (TAK) Stock Analysis: Exploring a 17.6% Potential Upside and Strong Revenue Growth", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Takeda Pharmaceutical Company (TAK) presents a compelling investment opportunity with a potential upside of 17.60% according to analyst consensus. The company, a global leader in specialty and generic drug manufacturing, boasts robust revenue growth of 10.20% and a diversified product portfolio. Despite challenges like negative EPS, its strong free cash flow and commitment to shareholder returns via a 3.26% dividend yield make it an attractive consideration for investors.", "age_days": 4.1, "is_stale": false, "sentiment": "positive", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.directorstalkinterviews.com/takeda-pharmaceutical-company-l-tak-stock-analysis-exploring-a-17-6-potential-upside-and-strong-revenue-growth/4121263186", "source_name": "DirectorsTalk Interviews", "published_at": "2026-09-21T10:07:00", "tone_signals": ["Operating growth"], "company_focus": 1.0, "freshness_pct": 57.0, "sentiment_pct": 76, "evidence_basis": "archived_article", "evidence_share": 57.2, "score_included": true, "duplicate_count": 2, "evidence_weight": 0.1766, "influence_label": "High", "event_confidence": 61, "company_focus_pct": 100, "evidence_strength": 66, "published_display": "21 Sep 2026 10:07", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "57.2"}, {"url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPbHh4U1FKQWdzYUZWT3FaaUU4c0d6U096VG11ZlN2TWw0bkFNS0JFTFB0b3dfaEJhQVZRV2hueVhMakdTdHJ6VTZJRTNzU0FnRHJDemhmbHN5TkxoVUIzNThCc1F1bkNJZ203Y2tNcS12ODFwS3lpOC1KZDVFRkNhc2lNNzk3ZWR1SzRiWEVyS2JsS0JpN0RWOFZrTDEwQ2FjUGZEOThMYTBuTU5MVVI5bUNqa3ptZGlEUVNYRC1zdldwQXZM?oc=5", "tier": "direct", "title": "Takeda Pharmaceutical Co cuts FY26 adj EPS to $2.96, sales to $29.1B", "topics": [], "summary": "", "age_days": 5.2, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPbHh4U1FKQWdzYUZWT3FaaUU4c0d6U096VG11ZlN2TWw0bkFNS0JFTFB0b3dfaEJhQVZRV2hueVhMakdTdHJ6VTZJRTNzU0FnRHJDemhmbHN5TkxoVUIzNThCc1F1bkNJZ203Y2tNcS12ODFwS3lpOC1KZDVFRkNhc2lNNzk3ZWR1SzRiWEVyS2JsS0JpN0RWOFZrTDEwQ2FjUGZEOThMYTBuTU5MVVI5bUNqa3ptZGlEUVNYRC1zdldwQXZM?oc=5", "source_name": "scanx.trade", "published_at": "2026-09-20T05:48:30+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 48.4, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.039818, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "20 Sep 2026 05:48", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTE9EamZqX1JNRjVScTFyOEs3MkdHejNlMWNXZlRLeG1mMjJLOF9nUFNZMUtVeEpQc3VzMGxSWWxaZjkxMDdMQ2M0VEtjZTlPWHY3?oc=5", "tier": "direct", "title": "Takeda Pharmaceutical Company Limited (TAK) stock price, news, quote and history", "topics": [], "summary": "", "age_days": 6.2, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "aggregator", "source_link": "https://news.google.com/rss/articles/CBMiUEFVX3lxTE9EamZqX1JNRjVScTFyOEs3MkdHejNlMWNXZlRLeG1mMjJLOF9nUFNZMUtVeEpQc3VzMGxSWWxaZjkxMDdMQ2M0VEtjZTlPWHY3?oc=5", "source_name": "Market source", "published_at": "2026-09-19T06:49:38+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 11.7, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.005732, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "19 Sep 2026 06:49", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://simplywall.st/stocks/jp/pharmaceuticals-biotech/tse-4502/takeda-pharmaceutical-shares/news/what-is-drawing-fresh-attention-to-takeda-pharmaceutical-tse", "tier": "direct", "title": "What Is Drawing Fresh Attention To Takeda Pharmaceutical (TSE:4502)?", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Takeda Pharmaceutical (TSE:4502) has received a boost from the U.S. FDA's acceptance of its New Drug Application for zasocitinib in plaque psoriasis, leading to a recent surge in its stock price. Despite a 9% undervaluation by analysts, concerns about generic competition and potential drug trial setbacks present risks. The company's pipeline in psoriasis and narcolepsy is seen as a key driver for future growth.", "age_days": 6.4, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://simplywall.st/stocks/jp/pharmaceuticals-biotech/tse-4502/takeda-pharmaceutical-shares/news/what-is-drawing-fresh-attention-to-takeda-pharmaceutical-tse", "source_name": "Simply Wall Street", "published_at": "2026-09-19T02:53:56", "tone_signals": ["Positive financial language"], "company_focus": 1.0, "freshness_pct": 41.4, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.038347, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "19 Sep 2026 02:53", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.bignewsnetwork.com/news/279315501/takeda-and-dr-reddy-laboratories-enter-into-exclusive-collaboration-to-promote-and-distribute-qdenga-in-india-pediatric-and-adult-private-market", "tier": "direct", "title": "Takeda and Dr. Reddy's Laboratories enter into exclusive collaboration to promote and distribute QDENGA in India's pediatric and adult private market", "topics": ["Life Sciences"], "summary": "Takeda and Dr. Reddy's Laboratories have announced an exclusive collaboration to promote and distribute Takeda's dengue vaccine, QDENGA, in India's private market for pediatric and adult vaccination. This partnership follows the vaccine's marketing authorization approval by India's CDSCO in July 2026, making it the country's first approved dengue vaccine. The collaboration aims to make QDENGA available in India by the first half of 2027, leveraging Dr. Reddy's extensive network to address the significant public health challenge posed by dengue in India.", "age_days": 6.9, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.bignewsnetwork.com/news/279315501/takeda-and-dr-reddy-laboratories-enter-into-exclusive-collaboration-to-promote-and-distribute-qdenga-in-india-pediatric-and-adult-private-market", "source_name": "Big News Network.com", "published_at": "2026-09-18T14:10:08", "tone_signals": ["Strategic partnership"], "company_focus": 1.0, "freshness_pct": 9.2, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.006465, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "18 Sep 2026 14:10", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.bradenton.com/living/article317290295.html", "tier": "direct", "title": "India's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in India", "topics": ["Life Sciences", "Mergers And Acquisitions"], "summary": "Dr Reddy's Laboratories has signed an agreement with Takeda Pharmaceutical to distribute and promote the Qdenga dengue vaccine in India. The vaccine, approved by India's drug regulator for children and adults, is expected to be available in early 2027. This partnership addresses the significant public health challenge posed by dengue, a rapidly spreading mosquito-borne disease.", "age_days": 6.9, "is_stale": false, "sentiment": "neutral", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "publisher", "source_link": "https://www.bradenton.com/living/article317290295.html", "source_name": "Bradenton Herald", "published_at": "2026-09-18T14:10:08", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 50.6, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.042038, "influence_label": "None", "event_confidence": 93, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "18 Sep 2026 14:10", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://finance.yahoo.com/healthcare/articles/dr-reddy-apos-takeda-sign-101709599.html", "tier": "direct", "title": "Dr. Reddy's, Takeda Sign Deal to Distribute QDENGA Dengue Vaccine in India", "topics": [], "summary": "", "age_days": 7.0, "is_stale": false, "sentiment": "neutral", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/healthcare/articles/dr-reddy-apos-takeda-sign-101709599.html", "source_name": "MT Newswires", "published_at": "2026-09-18T10:17:09+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 49.8, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.036846, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "18 Sep 2026 10:17", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.tipranks.com/stocks/gb:0a87/earnings/q4-2022-report", "tier": "direct", "title": "Takeda Pharmaceutical Company (0A87) Q4 2022 Earnings Report - Results, Call & Slides", "topics": ["Earnings", "Life Sciences"], "summary": "This article provides the Q4 2022 earnings report for Takeda Pharmaceutical Company (0A87), detailing actual EPS of $0.07 versus a consensus of $0.05, and actual revenue of $7.22 billion against an expected $7.16 billion. It includes a link to the earnings call audio and slide deck, and lists upcoming and historical earnings dates and results. The report indicates Takeda beat both EPS and revenue expectations for the quarter.", "age_days": 7.1, "is_stale": false, "sentiment": "negative", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.tipranks.com/stocks/gb:0a87/earnings/q4-2022-report", "source_name": "TipRanks", "published_at": "2026-09-18T09:14:30", "tone_signals": ["Positive financial language"], "company_focus": 1.0, "freshness_pct": 37.4, "sentiment_pct": 43, "evidence_basis": "archived_article", "evidence_share": 15.5, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.047741, "influence_label": "Medium", "event_confidence": 69, "company_focus_pct": 100, "evidence_strength": 40, "published_display": "18 Sep 2026 09:14", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "15.5"}, {"url": "https://finance.yahoo.com/healthcare/articles/takeda-employees-select-four-global-050000947.html", "tier": "direct", "title": "Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems", "topics": ["Climate Change", "Corporate Social Responsibility", "Global Partnerships", "Healthcare"], "summary": "2026 Awardees are Corus International,Humanity & Inclusion Handicap International, Kwame Nkrumah University of Science and Technology (KNUST) and Terre des hommes Foundation (Tdh) Commitment of USD 22.2 Million Increases Takeda's Total Global CSR Program Contributions to USD 260.9 Million Across 42 Diverse Collaborations Worldwide, With 20 Currently Ongoing in 42 Countries OSAKA, Japan & CAMBRIDGE, Mass., September 18, 2026--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE: TAK) announced that it has awarded a total of USD 22.2 million to four new Global Corporate Social Responsibility (CSR) partners as", "age_days": 7.3, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "press_release", "source_link": "https://finance.yahoo.com/healthcare/articles/takeda-employees-select-four-global-050000947.html", "source_name": "Business Wire", "published_at": "2026-09-18T05:00:00+00:00", "tone_signals": [], "company_focus": 0.78, "freshness_pct": 8.1, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "evidence_weight": 0.004037, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 78, "evidence_strength": 0, "published_display": "18 Sep 2026 05:00", "direction_included": false, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.benzinga.com/news/26/09/61841313/full-transcript-takeda-pharmaceutical-co-q1-2026-earnings-call", "tier": "direct", "title": "Full Transcript: Takeda Pharmaceutical Co Q1 2026 Earnings Call", "topics": ["Earnings", "Finance", "Life Sciences"], "summary": "Takeda Pharmaceutical Co reported Q1 2026 results, showing core revenue and operating profit declines of 0.5% at constant exchange rates, aligning with expectations. The company is focused on its Two-Horizon strategy, with key product launches for Orzafl, Rusfertide, and Zazositinib expected in late 2026 and early 2027, backed by a robust R&D pipeline and ongoing transformation programs. Takeda reaffirmed its full-year guidance and commitment to strong free cash flow and financial discipline, with a Capital Markets Day scheduled for December 11, 2026, to detail its long-term ambitions.", "age_days": 7.4, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.benzinga.com/news/26/09/61841313/full-transcript-takeda-pharmaceutical-co-q1-2026-earnings-call", "source_name": "Benzinga", "published_at": "2026-09-18T02:53:56", "tone_signals": ["Operating deterioration"], "company_focus": 1.0, "freshness_pct": 36.1, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "evidence_weight": 0.051808, "influence_label": "None", "event_confidence": 69, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "18 Sep 2026 02:53", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://finance.yahoo.com/healthcare/articles/takeda-pharmaceutical-tak-gets-priority-170819495.html", "tier": "direct", "title": "Takeda Pharmaceutical (TAK) Gets Priority Review. Can Zasocitinib Win in Psoriasis?", "topics": ["Clinical Trials", "Fda Approval", "Pharma"], "summary": "Takeda Pharmaceutical Company Limited (NYSE:TAK) announced on September 14 that the FDA accepted its New Drug Application for zasocitinib under priority review for adults with moderate-to-severe plaque psoriasis. The target action date falls in the first quarter of calendar 2027, creating a defined regulatory window for the investigational once-daily oral treatment. Zasocitinib inhibits tyrosine kinase 2, or TYK2, which participates in inflammatory signaling. For investors, the opportunity rests on combining meaningful skin clearance with oral convenience. Approval, prescribing restrictions an", "age_days": 7.8, "is_stale": false, "sentiment": "neutral", "event_type": "regulatory", "tier_label": "Direct company coverage", "event_label": "Regulatory and legal", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/healthcare/articles/takeda-pharmaceutical-tak-gets-priority-170819495.html", "source_name": "Insider Monkey", "published_at": "2026-09-17T17:08:19+00:00", "tone_signals": ["Negative financial language"], "company_focus": 1.0, "freshness_pct": 46.4, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "evidence_weight": 0.057582, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "17 Sep 2026 17:08", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPNHVUb0JfaDlmM0w0SDJOTHN1b0k5UER1c3NOVTVjWWRZcU5vc21FMHVONl9GMFJZamtFNno5WnN2S0N6LWlUV2NzY29WaGtEc205X2VXYzNRdUxXREdmTTBWdkc0ZzM3eGRocG8xWXIxbmhYM1NzeUgzbWRPemdPTUx4dUNQWnlVOUpjMWY4cFFSYWl3STRwaDNqbkk4VGpGWlkyeXFQd1lldHhnQ1BKMFdmSGp6TXY5OW5TNzQ4RGM3Q3VxZDhTVk9ZTlBFYlNwaU1HNVRB?oc=5", "tier": "direct", "title": "Takeda Pharmaceutical (TAK) Insider Sale: Chief Transformation O", "topics": [], "summary": "", "age_days": 9.3, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPNHVUb0JfaDlmM0w0SDJOTHN1b0k5UER1c3NOVTVjWWRZcU5vc21FMHVONl9GMFJZamtFNno5WnN2S0N6LWlUV2NzY29WaGtEc205X2VXYzNRdUxXREdmTTBWdkc0ZzM3eGRocG8xWXIxbmhYM1NzeUgzbWRPemdPTUx4dUNQWnlVOUpjMWY4cFFSYWl3STRwaDNqbkk4VGpGWlkyeXFQd1lldHhnQ1BKMFdmSGp6TXY5OW5TNzQ4RGM3Q3VxZDhTVk9ZTlBFYlNwaU1HNVRB?oc=5", "source_name": "GuruFocus", "published_at": "2026-09-16T04:19:48+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 4.0, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.002133, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "16 Sep 2026 04:19", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://finance.yahoo.com/healthcare/articles/takeda-apos-investigational-plaque-psoriasis-084219387.html", "tier": "direct", "title": "Takeda's Investigational Plaque Psoriasis Drug Accepted for Priority Review by US FDA", "topics": [], "summary": "", "age_days": 11.1, "is_stale": false, "sentiment": "neutral", "event_type": "regulatory", "tier_label": "Direct company coverage", "event_label": "Regulatory and legal", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/healthcare/articles/takeda-apos-investigational-plaque-psoriasis-084219387.html", "source_name": "MT Newswires", "published_at": "2026-09-14T08:42:19+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 33.3, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.031477, "influence_label": "None", "event_confidence": 69, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "14 Sep 2026 08:42", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.investing.com/news/company-news/fda-accepts-takedas-zasocitinib-application-for-plaque-psoriasis-93CH-4898864", "tier": "direct", "title": "FDA accepts Takeda\u2019s zasocitinib application for plaque psoriasis", "topics": ["Biotech", "Clinical Trials", "Earnings", "Fda Approval", "Life Sciences", "Pharma"], "summary": "The FDA has accepted Takeda's New Drug Application for zasocitinib (TAK-279) for moderate-to-severe plaque psoriasis, granting it Priority Review with a target action date in Q1 2027. This investigational oral drug demonstrated significant skin clearance in Phase 3 studies, with approximately 70% of patients achieving clear or almost clear skin by week 16. The European Medicines Agency also accepted Takeda\u2019s marketing authorization application for the drug.", "age_days": 11.2, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.investing.com/news/company-news/fda-accepts-takedas-zasocitinib-application-for-plaque-psoriasis-93CH-4898864", "source_name": "Investing.com", "published_at": "2026-09-14T07:02:45", "tone_signals": [], "company_focus": 0.78, "freshness_pct": 21.2, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 4, "evidence_weight": 0.021342, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 78, "evidence_strength": 0, "published_display": "14 Sep 2026 07:02", "direction_included": false, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE9JcW1uMzZ6clAzS0hORkM4MXppTTRMenUxcEhSLUZGREw2ampFekpMUE82Si1VakVfME5pZDJKbnF3Qi1SbGlxNFFjdy1vSDJBQTZOVk9B?oc=5", "tier": "direct", "title": "Takeda Pharmaceutical (TAK) Stock Price, News & Analysis $TAK", "topics": [], "summary": "", "age_days": 14.2, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE9JcW1uMzZ6clAzS0hORkM4MXppTTRMenUxcEhSLUZGREw2ampFekpMUE82Si1VakVfME5pZDJKbnF3Qi1SbGlxNFFjdy1vSDJBQTZOVk9B?oc=5", "source_name": "MarketBeat", "published_at": "2026-09-11T07:00:00+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 0.7, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.000392, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "11 Sep 2026 07:00", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.japantimes.co.jp/news/2026/09/11/japan/doyukai-hasegawa-dies", "tier": "direct", "title": "Former head of Takeda Pharmaceutical dies at 80", "topics": ["Finance", "Life Sciences"], "summary": "Yasuchika Hasegawa, former president of Takeda Pharmaceutical and former chair of the Japan Association of Corporate Executives, died at 80 on July 3 in Tokyo. He was instrumental in Takeda Pharmaceutical's globalization, overseeing a major acquisition and inviting its first foreign president. Hasegawa was also recognized for his leadership during the 2011 earthquake and tsunami disaster and his contributions to the Trans-Pacific Partnership deal.", "age_days": 14.1, "is_stale": false, "sentiment": "neutral", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "publisher", "source_link": "https://www.japantimes.co.jp/news/2026/09/11/japan/doyukai-hasegawa-dies", "source_name": "The Japan Times", "published_at": "2026-09-11T07:56:35", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 24.6, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.02129, "influence_label": "None", "event_confidence": 77, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "11 Sep 2026 07:56", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPbHh4U1FKQWdzYUZWT3FaaUU4c0d6U096VG11ZlN2TWw0bkFNS0JFTFB0b3dfaEJhQVZRV2hueVhMakdTdHJ6VTZJRTNzU0FnRHJDemhmbHN5TkxoVUIzNThCc1F1bkNJZ203Y2tNcS12ODFwS3lpOC1KZDVFRkNhc2lNNzk3ZWR1SzRiWEVyS2JsS0JpN0RWOFZrTDEwQ2FjUGZEOThMYTBuTU5MVVI5bUNqa3ptZGlEUVNYRC1zdldwQXZM?oc=5", "tier": "direct", "title": "Takeda Pharmaceutical Co cuts FY26 adj EPS to $2.96, sales to $29.1B", "topics": [], "summary": "", "age_days": 14.5, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPbHh4U1FKQWdzYUZWT3FaaUU4c0d6U096VG11ZlN2TWw0bkFNS0JFTFB0b3dfaEJhQVZRV2hueVhMakdTdHJ6VTZJRTNzU0FnRHJDemhmbHN5TkxoVUIzNThCc1F1bkNJZ203Y2tNcS12ODFwS3lpOC1KZDVFRkNhc2lNNzk3ZWR1SzRiWEVyS2JsS0JpN0RWOFZrTDEwQ2FjUGZEOThMYTBuTU5MVVI5bUNqa3ptZGlEUVNYRC1zdldwQXZM?oc=5", "source_name": "scanx.trade", "published_at": "2026-09-10T23:31:11+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 13.4, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.011027, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "10 Sep 2026 23:31", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://finance.yahoo.com/healthcare/articles/andy-plump-architect-takeda-r-112400854.html", "tier": "direct", "title": "Andy Plump, architect of Takeda\u2019s R&D overhaul, to retire next year", "topics": [], "summary": "", "age_days": 15.0, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/healthcare/articles/andy-plump-architect-takeda-r-112400854.html", "source_name": "BioPharma Dive", "published_at": "2026-09-10T11:24:00+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 0.6, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.000295, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "10 Sep 2026 11:24", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://finance.yahoo.com/healthcare/articles/trialbee-present-takeda-showcase-ai-130000891.html", "tier": "direct", "title": "Trialbee to Present with Takeda, Showcase AI for Clinical Sites, and Unveil AI-Powered Patient Screening at DPHARM 2026", "topics": ["AI", "Clinical Trials", "Healthcare", "Innovation", "Patient Recruitment"], "summary": "Trialbee continues to bring fresh innovation to clinical trials with its Honey Platform\u2122, demonstrating how AI is reshaping patient recruitment \u2013 and where it goes from here MALMO, Sweden & WILMINGTON, Del., September 09, 2026--(BUSINESS WIRE)--Trialbee, the global patient recruitment leader reimagining clinical trials with AI, will present alongside Takeda at DPHARM 2026 taking place September 15\u201316 in Boston. During the event, Trialbee will unveil AI patient screening in its Honey Platform\u2122, the next release on the Applied AI Recruitment roadmap it published earlier this year. Trialbee will ", "age_days": 15.9, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "press_release", "source_link": "https://finance.yahoo.com/healthcare/articles/trialbee-present-takeda-showcase-ai-130000891.html", "source_name": "Business Wire", "published_at": "2026-09-09T13:00:00+00:00", "tone_signals": [], "company_focus": 0.78, "freshness_pct": 0.4, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "evidence_weight": 0.0002, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 78, "evidence_strength": 0, "published_display": "09 Sep 2026 13:00", "direction_included": false, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxPWnVNVW5ZSmZVU1JGS3A3T1ZhVTlkeXVJMExSSzE3VTFlNEFsZmozS2xaaVhTMVlyQlFCZFZVZm1SMEdfM3VDbmdta05nVXVoZ0NzbTNZMVduQjJKdWljRFloNFV3aVNlTWtzcE5OY0luUjBVSVpQNFQ5dWZ3NnVwUzUwTC05YXhqWHNaZDhzNUhCOFp5SjBtRTZYMXB1MllhaDFiNnpXQXdlTGsyZWV1WVN6SjRKcTluSmpwUjdGc1BoSzYxZEJPMmlOczhsVlZQYXc?oc=5", "tier": "direct", "title": "Takeda Pharmaceutical Company L (TAK) Stock Analysis: Exploring a 22.66% Upside Potential", "topics": [], "summary": "", "age_days": 18.1, "is_stale": false, "sentiment": "positive", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxPWnVNVW5ZSmZVU1JGS3A3T1ZhVTlkeXVJMExSSzE3VTFlNEFsZmozS2xaaVhTMVlyQlFCZFZVZm1SMEdfM3VDbmdta05nVXVoZ0NzbTNZMVduQjJKdWljRFloNFV3aVNlTWtzcE5OY0luUjBVSVpQNFQ5dWZ3NnVwUzUwTC05YXhqWHNaZDhzNUhCOFp5SjBtRTZYMXB1MllhaDFiNnpXQXdlTGsyZWV1WVN6SjRKcTluSmpwUjdGc1BoSzYxZEJPMmlOczhsVlZQYXc?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-09-07T09:20:08+00:00", "tone_signals": ["Positive valuation view"], "company_focus": 1.0, "freshness_pct": 0.2, "sentiment_pct": 59, "evidence_basis": "headline_only", "evidence_share": 0.1, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.000176, "influence_label": "Low", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 32, "published_display": "07 Sep 2026 09:20", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "<0.1"}, {"url": "https://finance.yahoo.com/markets/stocks/articles/takeda-pharmaceutical-insider-sold-shares-072914824.html", "tier": "direct", "title": "Takeda Pharmaceutical Insider Sold Shares Worth $2,148,372, According to a Recent SEC Filing", "topics": [], "summary": "", "age_days": 21.2, "is_stale": false, "sentiment": "negative", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/markets/stocks/articles/takeda-pharmaceutical-insider-sold-shares-072914824.html", "source_name": "MT Newswires", "published_at": "2026-09-04T07:29:14+00:00", "tone_signals": ["Institutional or insider selling"], "company_focus": 1.0, "freshness_pct": 0.1, "sentiment_pct": 42, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 5.8e-05, "influence_label": "Low", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 30, "published_display": "04 Sep 2026 07:29", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "<0.1"}, {"url": "https://www.marketbeat.com/stocks/NYSE/TAK/forecast", "tier": "direct", "title": "Takeda Pharmaceutical (TAK) Stock Forecast and Price Target 2026 $TAK", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Takeda Pharmaceutical (TAK) has a consensus \"Moderate Buy\" rating from Wall Street analysts, with 4 analysts covering the stock. The company recently received FDA approval for MIMRYLO and Japan approval for ORZEYFUL, expanding its therapeutic areas. Despite strong financial performance and product approvals, concerns exist regarding insider selling, regulatory challenges, a high P/E ratio, and potential new drug pricing deals.", "age_days": 22.8, "is_stale": false, "sentiment": "positive", "event_type": "analyst", "tier_label": "Direct company coverage", "event_label": "Analyst action", "source_kind": "publisher", "source_link": "https://www.marketbeat.com/stocks/NYSE/TAK/forecast", "source_name": "MarketBeat", "published_at": "2026-09-02T15:30:54", "tone_signals": ["Fda Approval"], "company_focus": 1.0, "freshness_pct": 0.5, "sentiment_pct": 59, "evidence_basis": "archived_article", "evidence_share": 0.2, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.000694, "influence_label": "Low", "event_confidence": 61, "company_focus_pct": 100, "evidence_strength": 32, "published_display": "02 Sep 2026 15:30", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0.2"}, {"url": "https://finance.yahoo.com/markets/stocks/articles/investors-undervaluing-takeda-pharmaceutical-co-134003598.html", "tier": "direct", "title": "Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?", "topics": ["Estimate Revisions", "Value Investing"], "summary": "While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies. Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use a variety of methods, including tried-and-true valuation metrics, to find these stocks. On", "age_days": 22.9, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/markets/stocks/articles/investors-undervaluing-takeda-pharmaceutical-co-134003598.html", "source_name": "Zacks", "published_at": "2026-09-02T13:40:03+00:00", "tone_signals": ["Positive valuation view"], "company_focus": 0.78, "freshness_pct": 0.0, "sentiment_pct": 55, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "evidence_weight": 2.9e-05, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 78, "evidence_strength": 0, "published_display": "02 Sep 2026 13:40", "direction_included": false, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://finance.yahoo.com/healthcare/articles/takeda-weave-bio-collaborate-ai-095005482.html", "tier": "direct", "title": "Takeda and Weave Bio collaborate on AI-driven automation in drug development", "topics": [], "summary": "", "age_days": 23.1, "is_stale": false, "sentiment": "positive", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/healthcare/articles/takeda-weave-bio-collaborate-ai-095005482.html", "source_name": "Pharmaceutical Technology", "published_at": "2026-09-02T09:50:05+00:00", "tone_signals": ["Strategic partnership"], "company_focus": 1.0, "freshness_pct": 0.0, "sentiment_pct": 59, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 3.1e-05, "influence_label": "Low", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 31, "published_display": "02 Sep 2026 09:50", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "<0.1"}, {"url": "https://finance.yahoo.com/healthcare/articles/weave-bio-announces-collaboration-takeda-130000815.html", "tier": "direct", "title": "Weave Bio Announces Collaboration with Takeda to Deploy AI-Native Regulatory Automation Across Key Drug Development Activities", "topics": ["AI", "Collaboration", "Drug Development", "Regulation"], "summary": "Co-authored IND submission preparation study results demonstrate ~97% reduction in time to first draft and 60% overall timeline compression SAN FRANCISCO, September 01, 2026--(BUSINESS WIRE)--Weave Bio, the leader in AI-native regulatory automation for drug development, today announced a collaboration with Takeda to deploy the Weave platform across 14 active programs in multiple global markets. The collaboration brings together Weave's AI capabilities and Takeda's regulatory expertise to support innovation in regulatory workflows. \"Regulatory communications are the most knowledge-intensive wor", "age_days": 23.9, "is_stale": false, "sentiment": "positive", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "press_release", "source_link": "https://finance.yahoo.com/healthcare/articles/weave-bio-announces-collaboration-takeda-130000815.html", "source_name": "Business Wire", "published_at": "2026-09-01T13:00:00+00:00", "tone_signals": ["Strategic partnership"], "company_focus": 0.78, "freshness_pct": 3.6, "sentiment_pct": 61, "evidence_basis": "archived_article", "evidence_share": 1.9, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.005968, "influence_label": "Low", "event_confidence": 53, "company_focus_pct": 78, "evidence_strength": 34, "published_display": "01 Sep 2026 13:00", "direction_included": true, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "1.9"}, {"url": "https://www.biopharmadive.com/news/fda-approve-mimrylo-takeda-protagonist-polycythemia-vera/829153", "tier": "direct", "title": "FDA OKs Takeda, Protagonist drug for rare blood cancer", "topics": ["Earnings", "Life Sciences"], "summary": "The FDA has approved Mimrylo, a drug developed by Takeda Pharmaceutical and Protagonist Therapeutics, for polycythemia vera, a rare blood cancer. Mimrylo is the first of its kind, mimicking the liver hormone hepcidin to control iron levels and red blood cell production, and has a broader-than-expected label. Analysts project its peak yearly sales could reach $2 billion or more for Takeda.", "age_days": 24.5, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.biopharmadive.com/news/fda-approve-mimrylo-takeda-protagonist-polycythemia-vera/829153", "source_name": "BioPharma Dive", "published_at": "2026-08-31T23:32:24", "tone_signals": ["Contract or approval won"], "company_focus": 0.78, "freshness_pct": 3.4, "sentiment_pct": 55, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.003827, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 78, "evidence_strength": 0, "published_display": "31 Aug 2026 23:32", "direction_included": false, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://finance.yahoo.com/healthcare/articles/market-chatter-takeda-other-biotech-195856162.html", "tier": "direct", "title": "Update: Market Chatter: Takeda, Other Biotech Firms to Announce New Drug Pricing Deals With White House", "topics": [], "summary": "", "age_days": 24.6, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/healthcare/articles/market-chatter-takeda-other-biotech-195856162.html", "source_name": "MT Newswires", "published_at": "2026-08-31T19:58:56+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 0.0, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 1e-05, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "31 Aug 2026 19:58", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTE9EamZqX1JNRjVScTFyOEs3MkdHejNlMWNXZlRLeG1mMjJLOF9nUFNZMUtVeEpQc3VzMGxSWWxaZjkxMDdMQ2M0VEtjZTlPWHY3?oc=5", "tier": "direct", "title": "Takeda Pharmaceutical Company Limited (TAK) stock price, news, quote and history", "topics": [], "summary": "", "age_days": 24.8, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "aggregator", "source_link": "https://news.google.com/rss/articles/CBMiUEFVX3lxTE9EamZqX1JNRjVScTFyOEs3MkdHejNlMWNXZlRLeG1mMjJLOF9nUFNZMUtVeEpQc3VzMGxSWWxaZjkxMDdMQ2M0VEtjZTlPWHY3?oc=5", "source_name": "Market source", "published_at": "2026-08-31T17:21:45+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 0.0, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 9e-06, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "31 Aug 2026 17:21", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://finance.yahoo.com/healthcare/articles/takeda-secures-fda-approval-first-163813261.html", "tier": "direct", "title": "Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug", "topics": ["Biotech", "Clinical Trials", "Fda Approval"], "summary": "On Friday, the U.S. Food and Drug Administration (FDA) approvedTakeda Pharmaceutical Co. Ltd.'s (NYSE:TAK) MIMRYLO (rusfertide) for polycythemia vera, a type of blood cancer. How MIMRYLO Combats Polycythemia Vera Polycythemia vera forces the human body to overproduce red blood cells. This harmful overproduction dramatically increases blood thickness. Increased viscosity places patients at high risk for life-threatening thrombotic events, which include severe complications like strokes, pulmonary embolisms, and deep vein thrombosis. To prevent these severe health events, medical providers focus", "age_days": 24.8, "is_stale": false, "sentiment": "positive", "event_type": "regulatory", "tier_label": "Direct company coverage", "event_label": "Regulatory and legal", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/healthcare/articles/takeda-secures-fda-approval-first-163813261.html", "source_name": "Benzinga", "published_at": "2026-08-31T16:38:13+00:00", "tone_signals": ["Contract or approval won"], "company_focus": 0.78, "freshness_pct": 8.6, "sentiment_pct": 67, "evidence_basis": "archived_article", "evidence_share": 5.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.015573, "influence_label": "Medium", "event_confidence": 53, "company_focus_pct": 78, "evidence_strength": 41, "published_display": "31 Aug 2026 16:38", "direction_included": true, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "5"}, {"url": "https://www.bizjournals.com/boston/news/2026/08/28/takeda-wins-approval-for-two-drugs-in-one-month.html", "tier": "direct", "title": "Takeda wins second drug approval in August as it eyes return to growth", "topics": ["Earnings", "Life Sciences"], "summary": "Takeda secured two drug approvals in August for blood cancer and narcolepsy. These approvals are crucial as the biotech company navigates short-term generic competition and aims to achieve sustainable revenue and profit growth in fiscal 2025. The company is also preparing to move into a new global R&D center in Cambridge.", "age_days": 25.1, "is_stale": false, "sentiment": "positive", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.bizjournals.com/boston/news/2026/08/28/takeda-wins-approval-for-two-drugs-in-one-month.html", "source_name": "The Business Journals", "published_at": "2026-08-31T10:02:45", "tone_signals": ["Contract or approval won"], "company_focus": 0.78, "freshness_pct": 3.1, "sentiment_pct": 67, "evidence_basis": "archived_article", "evidence_share": 1.6, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.004885, "influence_label": "Medium", "event_confidence": 53, "company_focus_pct": 78, "evidence_strength": 40, "published_display": "31 Aug 2026 10:02", "direction_included": true, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "1.6"}, {"url": "https://seekingalpha.com/news/4638031-takeda-gains-approval-rusfertide-polycythemia-vera?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "tier": "direct", "title": "Takeda gains approval of rusfertide for polycythemia vera", "topics": ["Blood Cancer", "Clinical Trials", "Fda Approval", "Healthcare", "Pharma"], "summary": "[Polycythemia vera, artwork] Dr_Microbe/iStock via Getty Images * The US FDA approved Takeda Pharmaceutical's (TAK [https://seekingalpha.com/symbol/TAK]) Mimrylo (rusfertide), a first-in-class treatment for the rare blood disorder polycythemia vera. * Mimrylo works by mimicking hepcidin, a hormone that naturally regulates iron. The drug limits the iron in the body to make new red blood cells, cutting their their overproduction and mainiaining healthy red blood cell levels. * Approval was based [https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-its-kind-polycythemia-ve", "age_days": 27.6, "is_stale": false, "sentiment": "positive", "event_type": "regulatory", "tier_label": "Direct company coverage", "event_label": "Regulatory and legal", "source_kind": "publisher", "source_link": "https://seekingalpha.com/news/4638031-takeda-gains-approval-rusfertide-polycythemia-vera?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_name": "seekingalpha.com", "published_at": "2026-08-28T21:44:35+00:00", "tone_signals": ["Contract or approval won"], "company_focus": 0.78, "freshness_pct": 6.5, "sentiment_pct": 62, "evidence_basis": "archived_article", "evidence_share": 3.4, "score_included": true, "duplicate_count": 2, "evidence_weight": 0.010582, "influence_label": "Low", "event_confidence": 53, "company_focus_pct": 78, "evidence_strength": 35, "published_display": "28 Aug 2026 21:44", "direction_included": true, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "3.4"}, {"url": "https://www.fiercepharma.com/pharma/takeda-bolsters-blood-cancer-portfolio-fda-approval-mimrylo-polycythemia-vera", "tier": "direct", "title": "Takeda bolsters blood cancer portfolio with FDA nod for Mimrylo in polycythemia vera", "topics": ["Life Sciences"], "summary": "Takeda has received FDA approval for Mimrylo (rusfertide) to treat polycythemia vera, a rare blood cancer. Mimrylo is a first-in-class drug that mimics hepcidin, regulating iron and thereby curtailing the overproduction of red blood cells. This approval marks another significant regulatory win for CEO Julie Kim and is expected to contribute to Takeda's future growth alongside two other new medicines.", "age_days": 27.6, "is_stale": false, "sentiment": "positive", "event_type": "regulatory", "tier_label": "Direct company coverage", "event_label": "Regulatory and legal", "source_kind": "publisher", "source_link": "https://www.fiercepharma.com/pharma/takeda-bolsters-blood-cancer-portfolio-fda-approval-mimrylo-polycythemia-vera", "source_name": "Fierce Pharma", "published_at": "2026-08-28T22:04:00", "tone_signals": ["Fda Approval"], "company_focus": 0.78, "freshness_pct": 6.5, "sentiment_pct": 57, "evidence_basis": "archived_article", "evidence_share": 2.5, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.007596, "influence_label": "Low", "event_confidence": 61, "company_focus_pct": 78, "evidence_strength": 29, "published_display": "28 Aug 2026 22:04", "direction_included": true, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "2.5"}, {"url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE9VNy1kRFNkNE9pdVRfV29fTEVONXpuajBWLThyYWxVRURfb2NjaG55Vzg5QkdvaHg1Rnpld2lvZTNpdHFXbWdnNi1JQmtVbFNpeXVYbUpya0xSTktlTS1wMmZ6bXBraDRSREVaVg?oc=5", "tier": "direct", "title": "TAK|Takeda Pharmaceutical Co Ltd|Price:18.030|", "topics": [], "summary": "", "age_days": 28.2, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMibEFVX3lxTE9VNy1kRFNkNE9pdVRfV29fTEVONXpuajBWLThyYWxVRURfb2NjaG55Vzg5QkdvaHg1Rnpld2lvZTNpdHFXbWdnNi1JQmtVbFNpeXVYbUpya0xSTktlTS1wMmZ6bXBraDRSREVaVg?oc=5", "source_name": "tradingkey.com", "published_at": "2026-08-28T07:00:00+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 0.0, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 3e-06, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "28 Aug 2026 07:00", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}], "by_tier": {"direct": [{"url": "https://www.takeda.com/our-impact/our-stories/climate-ready-healthcare-global-csr-programs", "tier": "direct", "title": "Climate-ready healthcare: Our 2026 global CSR programs", "topics": ["Life Sciences", "Economy Macro"], "summary": "Takeda announced its 2026 global Corporate Social Responsibility (CSR) programs, committing USD 22.2 million to four new multi-year projects aimed at strengthening climate-resilient health systems worldwide. These initiatives, chosen by Takeda employees, will support organizations like Corus International, Humanity & Inclusion \u2013 Handicap International, Kwame Nkrumah University of Science and Technology, and Terre des hommes Foundation in countries such as Nepal, Honduras, Peru, Ghana, Egypt, and Lebanon. The programs focus on areas including early warning systems, resilient service delivery, workforce capacity building, and greener practices to address the widespread impact of climate change on global health outcomes.", "age_days": 1.1, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "44b7017f91d6deed8bc41141265e391426c6c14c0ede3f53d62c24c73c6d2ff2", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.takeda.com/our-impact/our-stories/climate-ready-healthcare-global-csr-programs", "source_name": "Takeda Pharmaceuticals", "published_at": "2026-09-24T09:47:40", "source_names": ["Takeda Pharmaceuticals"], "target_scope": "Takeda announced its 2026 global Corporate Social Responsibility (CSR) programs, committing USD 22.2 million to four new multi-year projects aimed at strengthening climate-resilient health systems worldwide. These initiatives, chosen by Takeda employees, will support organizations like Corus International, Humanity & Inclusion \u2013 Handicap International, Kwame Nkrumah University of Science and Technology, and Terre des hommes Foundation in countries such as Nepal, Honduras, Peru, Ghana, Egypt, and Lebanon.", "tone_signals": ["Negative financial language"], "company_focus": 0.86, "cross_listing": false, "entity_mapped": true, "freshness_pct": 69.0, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.041109, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.45, "provider_symbols": ["TAK"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 86, "evidence_strength": 0, "published_display": "24 Sep 2026 09:47", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Company discussed", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TAK", "provider_directional_mass": 0.4262}, {"url": "https://ca.finance.yahoo.com/quote/4502.T", "tier": "direct", "title": "Takeda Pharmaceutical Company Limited (4502.T) Stock Price, News, Quote & History", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "This article provides comprehensive financial data for Takeda Pharmaceutical Company Limited (4502.T), including its current stock price, dividend information, key financial metrics, performance overview, and analyst insights. The company recently announced a cash dividend and has shown significant year-to-date and annual returns. Takeda operates in the pharmaceutical industry, focusing on gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience.", "age_days": 2.1, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage", "google_news"], "sentiment": "neutral", "story_key": "eebef7caa2c9982af882cc735df669ef11985a44d83d4718b05212f5ce9fe0a2", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://ca.finance.yahoo.com/quote/4502.T", "source_name": "Yahoo! Finance Canada", "published_at": "2026-09-23T09:47:40", "source_names": ["Yahoo! Finance Canada"], "target_scope": "Takeda Pharmaceutical Company Limited (4502.T) Stock Price, News, Quote & History This article provides comprehensive financial data for Takeda Pharmaceutical Company Limited (4502.T), including its current stock price, dividend information, key financial metrics, performance overview, and analyst insights. Takeda operates in the pharmaceutical industry, focusing on gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience.", "tone_signals": ["Capital returned"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 75.1, "sentiment_pct": 55, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 4, "durable_archive": false, "evidence_weight": 0.109182, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.531, "provider_symbols": ["TAK", "TAK.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "23 Sep 2026 09:47", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TAK", "provider_directional_mass": 0.1004}, {"url": "https://www.reuters.com/legal/litigation/roche-proposes-former-takeda-ceo-board-seat-2026-09-23", "tier": "direct", "title": "Roche proposes former Takeda CEO for board seat", "topics": ["Life Sciences"], "summary": "Roche announced its proposal to elect Christophe Weber, the former CEO of Takeda Pharmaceuticals, to its board of directors at its upcoming Annual General Meeting in March. Roche Chairman Severin Schwan stated that Weber's extensive knowledge of the healthcare industry and leadership experience would significantly strengthen the board. This move signals Roche's intention to enhance its leadership with seasoned pharmaceutical expertise.", "age_days": 2.3, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "709e64d81185fdcadd8ce5b2c33b1f4d8fa09a57e44147712f8b013a3c9b2d82", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "editorial_wire", "source_link": "https://www.reuters.com/legal/litigation/roche-proposes-former-takeda-ceo-board-seat-2026-09-23", "source_name": "Reuters", "published_at": "2026-09-23T05:12:00", "source_names": ["Reuters"], "target_scope": "Roche proposes former Takeda CEO for board seat Roche announced its proposal to elect Christophe Weber, the former CEO of Takeda Pharmaceuticals, to its board of directors at its upcoming Annual General Meeting in March. This move signals Roche's intention to enhance its leadership with seasoned pharmaceutical expertise.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 45.7, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.038868, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.72, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["TAK"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "23 Sep 2026 05:12", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TAK", "provider_directional_mass": 0.0471}, {"url": "https://www.asahi.com/ajw/articles/16813325", "tier": "direct", "title": "Takeda\u2019s new president aims to increase line of drug candidates", "topics": ["Earnings", "Life Sciences", "Mergers And Acquisitions"], "summary": "Julie Kim, the new president of Takeda Pharmaceutical Co., is focused on accelerating drug development through the integration of AI and new technologies. She aims to establish Takeda as a world leader in its priority fields by strengthening its drug pipeline, including three new medicines slated for release within the next year. Kim, the company's first female president, emphasizes the importance of a robust line of potential drug candidates for long-term growth, building on the globalization efforts initiated by her predecessor, Christophe Weber.", "age_days": 2.6, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage", "archive"], "sentiment": "neutral", "story_key": "bec0e73e28639bd29e1a7e32d20cefde7f9952b6f543fa882b90c14e2a0daad5", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "publisher", "source_link": "https://www.asahi.com/ajw/articles/16813325", "source_name": "\u671d\u65e5\u65b0\u805e", "published_at": "2026-09-22T21:53:56", "source_names": ["\u671d\u65e5\u65b0\u805e"], "target_scope": "Takeda\u2019s new president aims to increase line of drug candidates Julie Kim, the new president of Takeda Pharmaceutical Co., is focused on accelerating drug development through the integration of AI and new technologies. She aims to establish Takeda as a world leader in its priority fields by strengthening its drug pipeline, including three new medicines slated for release within the next year.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 77.6, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.067024, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 93, "model_confidence": 0.4, "provider_symbols": ["TAK", "TAK.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "22 Sep 2026 21:53", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TAK", "provider_directional_mass": 0.3455}, {"url": "https://www.ad-hoc-news.de/boerse/news/nebenwerte/takeda-pharmaceutical-stock-holds-at-usd-18-91-as-pipeline-advances/70156878", "tier": "direct", "title": "Takeda Pharmaceutical stock holds at USD 18.91 as pipeline advances", "topics": ["Financial Markets", "Life Sciences"], "summary": "Takeda Pharmaceutical's stock closed at USD 18.91 on September 21, 2026, maintaining its position as the company advanced its oncology pipeline. Recent data, including Phase 3 research for arcotatug tavatecan, were presented at the ESMO 2026 congress. Despite a consensus Buy rating from analysts, there is no published consensus price target, focusing investor attention on clinical progress rather than immediate financial forecasts.", "age_days": 2.8, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage", "archive"], "sentiment": "positive", "story_key": "aad9d5ba08b81f8675f0c784f52e4d23e916b1fae072aa4e178901b16ec78ec4", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.ad-hoc-news.de/boerse/news/nebenwerte/takeda-pharmaceutical-stock-holds-at-usd-18-91-as-pipeline-advances/70156878", "source_name": "AD HOC NEWS", "published_at": "2026-09-22T16:54:00", "source_names": ["AD HOC NEWS"], "target_scope": "Takeda Pharmaceutical stock holds at USD 18.91 as pipeline advances Takeda Pharmaceutical's stock closed at USD 18.91 on September 21, 2026, maintaining its position as the company advanced its oncology pipeline.", "tone_signals": ["Buy Rating"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 38.3, "sentiment_pct": 57, "evidence_basis": "archived_article", "evidence_share": 12.6, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.038794, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.537, "provider_symbols": ["TAK", "TAK.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 39, "published_display": "22 Sep 2026 16:54", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "12.6", "target_provider_symbol": "TAK", "provider_directional_mass": 0.2879}, {"url": "https://finance.yahoo.com/healthcare/articles/takeda-highlights-stage-oncology-pipeline-133000609.html", "tier": "direct", "title": "Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026", "topics": ["Clinical Trials", "Esmo", "Gastric Cancer", "Lung Cancer", "Oncology"], "summary": "Late-Breaking Abstract to Feature New Data from First Phase 3 Registrational Study of Arcotatug Tavatecan in Previously Treated Advanced Gastric Cancer TAK-928 Presentations Reinforce Potential in Patients with Immunotherapy-Resistant Non-Small Cell Lung Cancer (NSCLC) and Previously Untreated NSCLC Takeda Continues to Progress Clinical Development of Arcotatug Tavatecan and TAK-928; New Non-Squamous NSCLC Sub-Trial Added to Global Phase 3 MarsLight-11 Study Evaluating TAK-928 vs. Docetaxel Monotherapy OSAKA, Japan & CAMBRIDGE, Mass., September 22, 2026--(BUSINESS WIRE)--Takeda(TSE:4502/NYSE:T", "age_days": 2.9, "is_stale": false, "provider": "yfinance", "providers": ["archive", "yfinance"], "sentiment": "neutral", "story_key": "371fa206a6822bbf34edf424ac7ed7ae77e682455c3987e4339024a467e7b8ca", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "press_release", "source_link": "https://finance.yahoo.com/healthcare/articles/takeda-highlights-stage-oncology-pipeline-133000609.html", "source_name": "Business Wire", "published_at": "2026-09-22T13:30:00+00:00", "source_names": ["Business Wire"], "target_scope": "Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026 Late-Breaking Abstract to Feature New Data from First Phase 3 Registrational Study of Arcotatug Tavatecan in Previously Treated Advanced Gastric Cancer TAK-928 Presentations Reinforce Potential in Patients with Immunotherapy-Resistant Non-Small Cell Lung Cancer (NSCLC) and Previously Untreated NSCLC Takeda Continues to Progress Clinical Development of Arcotatug Tavatecan and TAK-928 Docetaxel Monotherapy OSAKA, Japan & CAMBRIDGE, Mass., September 22, 2026--(BUSINESS WIRE)--Takeda(TSE:4502/NYSE:T", "tone_signals": [], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 36.4, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "durable_archive": false, "evidence_weight": 0.016923, "influence_label": "None", "provider_symbol": "TAK.US", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["TAK", "TAK.ARCHIVE", "TAK.US", "TKPHF.US", "ULN.US"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 0, "published_display": "22 Sep 2026 13:30", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TAK", "provider_directional_mass": null}, {"url": "https://www.directorstalkinterviews.com/takeda-pharmaceutical-company-l-tak-stock-analysis-exploring-a-17-6-potential-upside-and-strong-revenue-growth/4121263186", "tier": "direct", "title": "Takeda Pharmaceutical Company L (TAK) Stock Analysis: Exploring a 17.6% Potential Upside and Strong Revenue Growth", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Takeda Pharmaceutical Company (TAK) presents a compelling investment opportunity with a potential upside of 17.60% according to analyst consensus. The company, a global leader in specialty and generic drug manufacturing, boasts robust revenue growth of 10.20% and a diversified product portfolio. Despite challenges like negative EPS, its strong free cash flow and commitment to shareholder returns via a 3.26% dividend yield make it an attractive consideration for investors.", "age_days": 4.1, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage", "google_news"], "sentiment": "positive", "story_key": "93b94f6cceeff2d799355710280727e1274c5e5cc899c5f25c8ee80446211c18", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.directorstalkinterviews.com/takeda-pharmaceutical-company-l-tak-stock-analysis-exploring-a-17-6-potential-upside-and-strong-revenue-growth/4121263186", "source_name": "DirectorsTalk Interviews", "published_at": "2026-09-21T10:07:00", "source_names": ["DirectorsTalk Interviews"], "target_scope": "Takeda Pharmaceutical Company L (TAK) Stock Analysis: Exploring a 17.6% Potential Upside and Strong Revenue Growth Takeda Pharmaceutical Company (TAK) presents a compelling investment opportunity with a potential upside of 17.60% according to analyst consensus.", "tone_signals": ["Operating growth"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 57.0, "sentiment_pct": 76, "evidence_basis": "archived_article", "evidence_share": 57.2, "score_included": true, "duplicate_count": 2, "durable_archive": false, "evidence_weight": 0.1766, "influence_label": "High", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 61, "model_confidence": 0.728, "provider_symbols": ["TAK", "TAK.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 66, "published_display": "21 Sep 2026 10:07", "direction_included": true, "sentiment_conflict": 0.079, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "57.2", "target_provider_symbol": "TAK", "provider_directional_mass": 0.531}, {"url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPbHh4U1FKQWdzYUZWT3FaaUU4c0d6U096VG11ZlN2TWw0bkFNS0JFTFB0b3dfaEJhQVZRV2hueVhMakdTdHJ6VTZJRTNzU0FnRHJDemhmbHN5TkxoVUIzNThCc1F1bkNJZ203Y2tNcS12ODFwS3lpOC1KZDVFRkNhc2lNNzk3ZWR1SzRiWEVyS2JsS0JpN0RWOFZrTDEwQ2FjUGZEOThMYTBuTU5MVVI5bUNqa3ptZGlEUVNYRC1zdldwQXZM?oc=5", "tier": "direct", "title": "Takeda Pharmaceutical Co cuts FY26 adj EPS to $2.96, sales to $29.1B", "topics": [], "summary": "", "age_days": 5.2, "is_stale": false, "provider": "google_news", "providers": ["google_news"], "sentiment": "neutral", "story_key": "09d8c62d79f797555fc7517d919ee8d4a39c3417bca00be17b3a162c6ede128e", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPbHh4U1FKQWdzYUZWT3FaaUU4c0d6U096VG11ZlN2TWw0bkFNS0JFTFB0b3dfaEJhQVZRV2hueVhMakdTdHJ6VTZJRTNzU0FnRHJDemhmbHN5TkxoVUIzNThCc1F1bkNJZ203Y2tNcS12ODFwS3lpOC1KZDVFRkNhc2lNNzk3ZWR1SzRiWEVyS2JsS0JpN0RWOFZrTDEwQ2FjUGZEOThMYTBuTU5MVVI5bUNqa3ptZGlEUVNYRC1zdldwQXZM?oc=5", "source_name": "scanx.trade", "published_at": "2026-09-20T05:48:30+00:00", "source_names": ["scanx.trade"], "target_scope": "Takeda Pharmaceutical Co cuts FY26 adj EPS to $2.96, sales to $29.1B", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 48.4, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.039818, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": ["TAK.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "20 Sep 2026 05:48", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TAK.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTE9EamZqX1JNRjVScTFyOEs3MkdHejNlMWNXZlRLeG1mMjJLOF9nUFNZMUtVeEpQc3VzMGxSWWxaZjkxMDdMQ2M0VEtjZTlPWHY3?oc=5", "tier": "direct", "title": "Takeda Pharmaceutical Company Limited (TAK) stock price, news, quote and history", "topics": [], "summary": "", "age_days": 6.2, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "neutral", "story_key": "7bb5153fea0014ebce5956d705c2d26c137f006bd559b4ce9ab67daf56023aa3", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "aggregator", "source_link": "https://news.google.com/rss/articles/CBMiUEFVX3lxTE9EamZqX1JNRjVScTFyOEs3MkdHejNlMWNXZlRLeG1mMjJLOF9nUFNZMUtVeEpQc3VzMGxSWWxaZjkxMDdMQ2M0VEtjZTlPWHY3?oc=5", "source_name": "Market source", "published_at": "2026-09-19T06:49:38+00:00", "source_names": ["Market source"], "target_scope": "Takeda Pharmaceutical Company Limited (TAK) stock price, news, quote and history", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 11.7, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.005732, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "google_news", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["TAK.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "19 Sep 2026 06:49", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TAK.ARCHIVE", "provider_directional_mass": null}, {"url": "https://simplywall.st/stocks/jp/pharmaceuticals-biotech/tse-4502/takeda-pharmaceutical-shares/news/what-is-drawing-fresh-attention-to-takeda-pharmaceutical-tse", "tier": "direct", "title": "What Is Drawing Fresh Attention To Takeda Pharmaceutical (TSE:4502)?", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Takeda Pharmaceutical (TSE:4502) has received a boost from the U.S. FDA's acceptance of its New Drug Application for zasocitinib in plaque psoriasis, leading to a recent surge in its stock price. Despite a 9% undervaluation by analysts, concerns about generic competition and potential drug trial setbacks present risks. The company's pipeline in psoriasis and narcolepsy is seen as a key driver for future growth.", "age_days": 6.4, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage", "archive"], "sentiment": "neutral", "story_key": "188bfaa02935fd7c7abde3fa6dfca693d5a434a8002810a7f1fb32f739146c37", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://simplywall.st/stocks/jp/pharmaceuticals-biotech/tse-4502/takeda-pharmaceutical-shares/news/what-is-drawing-fresh-attention-to-takeda-pharmaceutical-tse", "source_name": "Simply Wall Street", "published_at": "2026-09-19T02:53:56", "source_names": ["Simply Wall Street"], "target_scope": "What Is Drawing Fresh Attention To Takeda Pharmaceutical (TSE:4502)? Takeda Pharmaceutical (TSE:4502) has received a boost from the U.S.", "tone_signals": ["Positive financial language"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 41.4, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.038347, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.45, "provider_symbols": ["TAK", "TAK.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "19 Sep 2026 02:53", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TAK", "provider_directional_mass": 0.0203}, {"url": "https://www.bignewsnetwork.com/news/279315501/takeda-and-dr-reddy-laboratories-enter-into-exclusive-collaboration-to-promote-and-distribute-qdenga-in-india-pediatric-and-adult-private-market", "tier": "direct", "title": "Takeda and Dr. Reddy's Laboratories enter into exclusive collaboration to promote and distribute QDENGA in India's pediatric and adult private market", "topics": ["Life Sciences"], "summary": "Takeda and Dr. Reddy's Laboratories have announced an exclusive collaboration to promote and distribute Takeda's dengue vaccine, QDENGA, in India's private market for pediatric and adult vaccination. This partnership follows the vaccine's marketing authorization approval by India's CDSCO in July 2026, making it the country's first approved dengue vaccine. The collaboration aims to make QDENGA available in India by the first half of 2027, leveraging Dr. Reddy's extensive network to address the significant public health challenge posed by dengue in India.", "age_days": 6.9, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage", "archive"], "sentiment": "neutral", "story_key": "10bb29e1402375d2f1313bfbb4ae196214c1b65f0485e59f96f3a172add3f45c", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.bignewsnetwork.com/news/279315501/takeda-and-dr-reddy-laboratories-enter-into-exclusive-collaboration-to-promote-and-distribute-qdenga-in-india-pediatric-and-adult-private-market", "source_name": "Big News Network.com", "published_at": "2026-09-18T14:10:08", "source_names": ["Big News Network.com"], "target_scope": "Takeda and Dr. Takeda and Dr. Reddy's Laboratories have announced an exclusive collaboration to promote and distribute Takeda's dengue vaccine, QDENGA, in India's private market for pediatric and adult vaccination.", "tone_signals": ["Strategic partnership"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 9.2, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.006465, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.526, "provider_symbols": ["TAK", "TAK.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "18 Sep 2026 14:10", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TAK", "provider_directional_mass": 0.0259}, {"url": "https://www.bradenton.com/living/article317290295.html", "tier": "direct", "title": "India's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in India", "topics": ["Life Sciences", "Mergers And Acquisitions"], "summary": "Dr Reddy's Laboratories has signed an agreement with Takeda Pharmaceutical to distribute and promote the Qdenga dengue vaccine in India. The vaccine, approved by India's drug regulator for children and adults, is expected to be available in early 2027. This partnership addresses the significant public health challenge posed by dengue, a rapidly spreading mosquito-borne disease.", "age_days": 6.9, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "d3ad46956b31bebb1be8d0abe647290df7a5d1cddaf1caf0c420b778b9ee333c", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "publisher", "source_link": "https://www.bradenton.com/living/article317290295.html", "source_name": "Bradenton Herald", "published_at": "2026-09-18T14:10:08", "source_names": ["Bradenton Herald"], "target_scope": "India's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in India Dr Reddy's Laboratories has signed an agreement with Takeda Pharmaceutical to distribute and promote the Qdenga dengue vaccine in India.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 50.6, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.042038, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.941884, "archive_provider": "", "event_confidence": 93, "model_confidence": 0.4, "provider_symbols": ["TAK", "TAK.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "18 Sep 2026 14:10", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TAK", "provider_directional_mass": 0.3088}, {"url": "https://finance.yahoo.com/healthcare/articles/dr-reddy-apos-takeda-sign-101709599.html", "tier": "direct", "title": "Dr. Reddy's, Takeda Sign Deal to Distribute QDENGA Dengue Vaccine in India", "topics": [], "summary": "", "age_days": 7.0, "is_stale": false, "provider": "yfinance", "providers": ["archive", "yfinance"], "sentiment": "neutral", "story_key": "7dc2b6179f0ad9b9ae18bc0fe9b6851e96580dfbdb36b7fb49e3d5a035db2580", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/healthcare/articles/dr-reddy-apos-takeda-sign-101709599.html", "source_name": "MT Newswires", "published_at": "2026-09-18T10:17:09+00:00", "source_names": ["MT Newswires"], "target_scope": "Reddy's, Takeda Sign Deal to Distribute QDENGA Dengue Vaccine in India", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 49.8, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.036846, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": ["RDY", "TAK", "TAK.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "18 Sep 2026 10:17", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TAK", "provider_directional_mass": null}, {"url": "https://www.tipranks.com/stocks/gb:0a87/earnings/q4-2022-report", "tier": "direct", "title": "Takeda Pharmaceutical Company (0A87) Q4 2022 Earnings Report - Results, Call & Slides", "topics": ["Earnings", "Life Sciences"], "summary": "This article provides the Q4 2022 earnings report for Takeda Pharmaceutical Company (0A87), detailing actual EPS of $0.07 versus a consensus of $0.05, and actual revenue of $7.22 billion against an expected $7.16 billion. It includes a link to the earnings call audio and slide deck, and lists upcoming and historical earnings dates and results. The report indicates Takeda beat both EPS and revenue expectations for the quarter.", "age_days": 7.1, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage", "archive"], "sentiment": "negative", "story_key": "9d1b6a2dbf47a6e15710109c4c2955f7c8eb7f794347bef1ab8857ce1019a69b", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.tipranks.com/stocks/gb:0a87/earnings/q4-2022-report", "source_name": "TipRanks", "published_at": "2026-09-18T09:14:30", "source_names": ["TipRanks"], "target_scope": "Takeda Pharmaceutical Company (0A87) Q4 2022 Earnings Report - Results, Call & Slides This article provides the Q4 2022 earnings report for Takeda Pharmaceutical Company (0A87), detailing actual EPS of $0.07 versus a consensus of $0.05, and actual revenue of $7.22 billion against an expected $7.16 billion. The report indicates Takeda beat both EPS and revenue expectations for the quarter.", "tone_signals": ["Positive financial language"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 37.4, "sentiment_pct": 43, "evidence_basis": "archived_article", "evidence_share": 15.5, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.047741, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 69, "model_confidence": 0.442, "provider_symbols": ["TAK", "TAK.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 40, "published_display": "18 Sep 2026 09:14", "direction_included": true, "sentiment_conflict": 0.65, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "15.5", "target_provider_symbol": "TAK", "provider_directional_mass": 0.0045}, {"url": "https://finance.yahoo.com/healthcare/articles/takeda-employees-select-four-global-050000947.html", "tier": "direct", "title": "Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems", "topics": ["Climate Change", "Corporate Social Responsibility", "Global Partnerships", "Healthcare"], "summary": "2026 Awardees are Corus International,Humanity & Inclusion Handicap International, Kwame Nkrumah University of Science and Technology (KNUST) and Terre des hommes Foundation (Tdh) Commitment of USD 22.2 Million Increases Takeda's Total Global CSR Program Contributions to USD 260.9 Million Across 42 Diverse Collaborations Worldwide, With 20 Currently Ongoing in 42 Countries OSAKA, Japan & CAMBRIDGE, Mass., September 18, 2026--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE: TAK) announced that it has awarded a total of USD 22.2 million to four new Global Corporate Social Responsibility (CSR) partners as", "age_days": 7.3, "is_stale": false, "provider": "yfinance", "providers": ["archive", "yfinance"], "sentiment": "neutral", "story_key": "030deff16617d5bb5cbcbfb14a99a415415d93c0bf42bea241792727eb5ce417", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "press_release", "source_link": "https://finance.yahoo.com/healthcare/articles/takeda-employees-select-four-global-050000947.html", "source_name": "Business Wire", "published_at": "2026-09-18T05:00:00+00:00", "source_names": ["Business Wire"], "target_scope": "Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems 2026 Awardees are Corus International,Humanity & Inclusion Handicap International, Kwame Nkrumah University of Science and Technology (KNUST) and Terre des hommes Foundation (Tdh) Commitment of USD 22.2 Million Increases Takeda's Total Global CSR Program Contributions to USD 260.9 Million Across 42 Diverse Collaborations Worldwide, With 20 Currently Ongoing in 42 Countries OSAKA, Japan & CAMBRIDGE, Mass., September 18, 2026--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE: TAK) announced that it has awarded a total of USD 22.2 million to four new Global Corporate Social Responsibility (CSR) partners as", "tone_signals": [], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 8.1, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "durable_archive": false, "evidence_weight": 0.004037, "influence_label": "None", "provider_symbol": "TAK.US", "relevance_score": 0.88388, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["TAK", "TAK.ARCHIVE", "TAK.US", "TKPHF.US"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 0, "published_display": "18 Sep 2026 05:00", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TAK", "provider_directional_mass": null}, {"url": "https://www.benzinga.com/news/26/09/61841313/full-transcript-takeda-pharmaceutical-co-q1-2026-earnings-call", "tier": "direct", "title": "Full Transcript: Takeda Pharmaceutical Co Q1 2026 Earnings Call", "topics": ["Earnings", "Finance", "Life Sciences"], "summary": "Takeda Pharmaceutical Co reported Q1 2026 results, showing core revenue and operating profit declines of 0.5% at constant exchange rates, aligning with expectations. The company is focused on its Two-Horizon strategy, with key product launches for Orzafl, Rusfertide, and Zazositinib expected in late 2026 and early 2027, backed by a robust R&D pipeline and ongoing transformation programs. Takeda reaffirmed its full-year guidance and commitment to strong free cash flow and financial discipline, with a Capital Markets Day scheduled for December 11, 2026, to detail its long-term ambitions.", "age_days": 7.4, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage", "archive"], "sentiment": "neutral", "story_key": "747f2f288094db7472ff729acf68bf57a6964d0dda9b66cb5d43e2ab3d8bd5e9", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.benzinga.com/news/26/09/61841313/full-transcript-takeda-pharmaceutical-co-q1-2026-earnings-call", "source_name": "Benzinga", "published_at": "2026-09-18T02:53:56", "source_names": ["Benzinga"], "target_scope": "Full Transcript: Takeda Pharmaceutical Co Q1 2026 Earnings Call Takeda Pharmaceutical Co reported Q1 2026 results, showing core revenue and operating profit declines of 0.5% at constant exchange rates, aligning with expectations. Takeda reaffirmed its full-year guidance and commitment to strong free cash flow and financial discipline, with a Capital Markets Day scheduled for December 11, 2026, to detail its long-term ambitions.", "tone_signals": ["Operating deterioration"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 36.1, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "durable_archive": false, "evidence_weight": 0.051808, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 69, "model_confidence": 0.513, "provider_symbols": ["TAK", "TAK.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "18 Sep 2026 02:53", "direction_included": false, "sentiment_conflict": 0.195, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TAK", "provider_directional_mass": 0.3875}, {"url": "https://finance.yahoo.com/healthcare/articles/takeda-pharmaceutical-tak-gets-priority-170819495.html", "tier": "direct", "title": "Takeda Pharmaceutical (TAK) Gets Priority Review. Can Zasocitinib Win in Psoriasis?", "topics": ["Clinical Trials", "Fda Approval", "Pharma"], "summary": "Takeda Pharmaceutical Company Limited (NYSE:TAK) announced on September 14 that the FDA accepted its New Drug Application for zasocitinib under priority review for adults with moderate-to-severe plaque psoriasis. The target action date falls in the first quarter of calendar 2027, creating a defined regulatory window for the investigational once-daily oral treatment. Zasocitinib inhibits tyrosine kinase 2, or TYK2, which participates in inflammatory signaling. For investors, the opportunity rests on combining meaningful skin clearance with oral convenience. Approval, prescribing restrictions an", "age_days": 7.8, "is_stale": false, "provider": "yfinance", "providers": ["archive", "yfinance"], "sentiment": "neutral", "story_key": "7021c73ecde03407d158c0dab86a3ddb0ac5840890d381f7c4f3a3e926a0212e", "event_type": "regulatory", "tier_label": "Direct company coverage", "event_label": "Regulatory and legal", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/healthcare/articles/takeda-pharmaceutical-tak-gets-priority-170819495.html", "source_name": "Insider Monkey", "published_at": "2026-09-17T17:08:19+00:00", "source_names": ["Insider Monkey"], "target_scope": "Takeda Pharmaceutical (TAK) Gets Priority Review. Takeda Pharmaceutical Company Limited (NYSE:TAK) announced on September 14 that the FDA accepted its New Drug Application for zasocitinib under priority review for adults with moderate-to-severe plaque psoriasis.", "tone_signals": ["Negative financial language"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 46.4, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "durable_archive": false, "evidence_weight": 0.057582, "influence_label": "None", "provider_symbol": "TAK.US", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.45, "provider_symbols": ["TAK", "TAK.ARCHIVE", "TAK.US"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "17 Sep 2026 17:08", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TAK", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPNHVUb0JfaDlmM0w0SDJOTHN1b0k5UER1c3NOVTVjWWRZcU5vc21FMHVONl9GMFJZamtFNno5WnN2S0N6LWlUV2NzY29WaGtEc205X2VXYzNRdUxXREdmTTBWdkc0ZzM3eGRocG8xWXIxbmhYM1NzeUgzbWRPemdPTUx4dUNQWnlVOUpjMWY4cFFSYWl3STRwaDNqbkk4VGpGWlkyeXFQd1lldHhnQ1BKMFdmSGp6TXY5OW5TNzQ4RGM3Q3VxZDhTVk9ZTlBFYlNwaU1HNVRB?oc=5", "tier": "direct", "title": "Takeda Pharmaceutical (TAK) Insider Sale: Chief Transformation O", "topics": [], "summary": "", "age_days": 9.3, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "neutral", "story_key": "9e3a4557c55bc0fd6f8e70b3364608ffe113fc1960d4fe45db67a875e2721867", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPNHVUb0JfaDlmM0w0SDJOTHN1b0k5UER1c3NOVTVjWWRZcU5vc21FMHVONl9GMFJZamtFNno5WnN2S0N6LWlUV2NzY29WaGtEc205X2VXYzNRdUxXREdmTTBWdkc0ZzM3eGRocG8xWXIxbmhYM1NzeUgzbWRPemdPTUx4dUNQWnlVOUpjMWY4cFFSYWl3STRwaDNqbkk4VGpGWlkyeXFQd1lldHhnQ1BKMFdmSGp6TXY5OW5TNzQ4RGM3Q3VxZDhTVk9ZTlBFYlNwaU1HNVRB?oc=5", "source_name": "GuruFocus", "published_at": "2026-09-16T04:19:48+00:00", "source_names": ["GuruFocus"], "target_scope": "Takeda Pharmaceutical (TAK) Insider Sale: Chief Transformation O", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 4.0, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.002133, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "google_news", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["TAK.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "16 Sep 2026 04:19", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TAK.ARCHIVE", "provider_directional_mass": null}, {"url": "https://finance.yahoo.com/healthcare/articles/takeda-apos-investigational-plaque-psoriasis-084219387.html", "tier": "direct", "title": "Takeda's Investigational Plaque Psoriasis Drug Accepted for Priority Review by US FDA", "topics": [], "summary": "", "age_days": 11.1, "is_stale": false, "provider": "yfinance", "providers": ["archive", "yfinance"], "sentiment": "neutral", "story_key": "39edac77c46c752444afa182d726c470d35787e756de464719be146d91489754", "event_type": "regulatory", "tier_label": "Direct company coverage", "event_label": "Regulatory and legal", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/healthcare/articles/takeda-apos-investigational-plaque-psoriasis-084219387.html", "source_name": "MT Newswires", "published_at": "2026-09-14T08:42:19+00:00", "source_names": ["MT Newswires"], "target_scope": "Takeda's Investigational Plaque Psoriasis Drug Accepted for Priority Review by US FDA", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 33.3, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.031477, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 69, "model_confidence": 0.4, "provider_symbols": ["TAK", "TAK.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "14 Sep 2026 08:42", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TAK", "provider_directional_mass": null}, {"url": "https://www.investing.com/news/company-news/fda-accepts-takedas-zasocitinib-application-for-plaque-psoriasis-93CH-4898864", "tier": "direct", "title": "FDA accepts Takeda\u2019s zasocitinib application for plaque psoriasis", "topics": ["Biotech", "Clinical Trials", "Earnings", "Fda Approval", "Life Sciences", "Pharma"], "summary": "The FDA has accepted Takeda's New Drug Application for zasocitinib (TAK-279) for moderate-to-severe plaque psoriasis, granting it Priority Review with a target action date in Q1 2027. This investigational oral drug demonstrated significant skin clearance in Phase 3 studies, with approximately 70% of patients achieving clear or almost clear skin by week 16. The European Medicines Agency also accepted Takeda\u2019s marketing authorization application for the drug.", "age_days": 11.2, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage", "archive"], "sentiment": "neutral", "story_key": "1e68e3a701f1edd1f8f327eb83f38af9a8f78c464f168be39c2797c1bcd521d8", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.investing.com/news/company-news/fda-accepts-takedas-zasocitinib-application-for-plaque-psoriasis-93CH-4898864", "source_name": "Investing.com", "published_at": "2026-09-14T07:02:45", "source_names": ["Investing.com"], "target_scope": "FDA accepts Takeda\u2019s zasocitinib application for plaque psoriasis The FDA has accepted Takeda's New Drug Application for zasocitinib (TAK-279) for moderate-to-severe plaque psoriasis, granting it Priority Review with a target action date in Q1 2027. The European Medicines Agency also accepted Takeda\u2019s marketing authorization application for the drug.", "tone_signals": [], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 21.2, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 4, "durable_archive": false, "evidence_weight": 0.021342, "influence_label": "None", "provider_symbol": "TAK.US", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": ["TAK", "TAK.ARCHIVE", "TAK.US", "TKPHF.US"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 0, "published_display": "14 Sep 2026 07:02", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TAK", "provider_directional_mass": 0.4495}, {"url": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE9JcW1uMzZ6clAzS0hORkM4MXppTTRMenUxcEhSLUZGREw2ampFekpMUE82Si1VakVfME5pZDJKbnF3Qi1SbGlxNFFjdy1vSDJBQTZOVk9B?oc=5", "tier": "direct", "title": "Takeda Pharmaceutical (TAK) Stock Price, News & Analysis $TAK", "topics": [], "summary": "", "age_days": 14.2, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "neutral", "story_key": "efab0e9832e6cf19eb5de39af6deba3a85aff7bd006ff5ae373b64cc73d85dc9", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE9JcW1uMzZ6clAzS0hORkM4MXppTTRMenUxcEhSLUZGREw2ampFekpMUE82Si1VakVfME5pZDJKbnF3Qi1SbGlxNFFjdy1vSDJBQTZOVk9B?oc=5", "source_name": "MarketBeat", "published_at": "2026-09-11T07:00:00+00:00", "source_names": ["MarketBeat"], "target_scope": "Takeda Pharmaceutical (TAK) Stock Price, News & Analysis $TAK", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.7, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.000392, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "google_news", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["TAK.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "11 Sep 2026 07:00", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TAK.ARCHIVE", "provider_directional_mass": null}, {"url": "https://www.japantimes.co.jp/news/2026/09/11/japan/doyukai-hasegawa-dies", "tier": "direct", "title": "Former head of Takeda Pharmaceutical dies at 80", "topics": ["Finance", "Life Sciences"], "summary": "Yasuchika Hasegawa, former president of Takeda Pharmaceutical and former chair of the Japan Association of Corporate Executives, died at 80 on July 3 in Tokyo. He was instrumental in Takeda Pharmaceutical's globalization, overseeing a major acquisition and inviting its first foreign president. Hasegawa was also recognized for his leadership during the 2011 earthquake and tsunami disaster and his contributions to the Trans-Pacific Partnership deal.", "age_days": 14.1, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage", "archive"], "sentiment": "neutral", "story_key": "1079b6ae4662ba362defbd681f3fb34695c9d6d251412b01490eee36cfd63533", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "publisher", "source_link": "https://www.japantimes.co.jp/news/2026/09/11/japan/doyukai-hasegawa-dies", "source_name": "The Japan Times", "published_at": "2026-09-11T07:56:35", "source_names": ["The Japan Times"], "target_scope": "Former head of Takeda Pharmaceutical dies at 80 Yasuchika Hasegawa, former president of Takeda Pharmaceutical and former chair of the Japan Association of Corporate Executives, died at 80 on July 3 in Tokyo. He was instrumental in Takeda Pharmaceutical's globalization, overseeing a major acquisition and inviting its first foreign president.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 24.6, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.02129, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 77, "model_confidence": 0.4, "provider_symbols": ["TAK", "TAK.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "11 Sep 2026 07:56", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TAK", "provider_directional_mass": 0.0378}, {"url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPbHh4U1FKQWdzYUZWT3FaaUU4c0d6U096VG11ZlN2TWw0bkFNS0JFTFB0b3dfaEJhQVZRV2hueVhMakdTdHJ6VTZJRTNzU0FnRHJDemhmbHN5TkxoVUIzNThCc1F1bkNJZ203Y2tNcS12ODFwS3lpOC1KZDVFRkNhc2lNNzk3ZWR1SzRiWEVyS2JsS0JpN0RWOFZrTDEwQ2FjUGZEOThMYTBuTU5MVVI5bUNqa3ptZGlEUVNYRC1zdldwQXZM?oc=5", "tier": "direct", "title": "Takeda Pharmaceutical Co cuts FY26 adj EPS to $2.96, sales to $29.1B", "topics": [], "summary": "", "age_days": 14.5, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "neutral", "story_key": "09d8c62d79f797555fc7517d919ee8d4a39c3417bca00be17b3a162c6ede128e", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPbHh4U1FKQWdzYUZWT3FaaUU4c0d6U096VG11ZlN2TWw0bkFNS0JFTFB0b3dfaEJhQVZRV2hueVhMakdTdHJ6VTZJRTNzU0FnRHJDemhmbHN5TkxoVUIzNThCc1F1bkNJZ203Y2tNcS12ODFwS3lpOC1KZDVFRkNhc2lNNzk3ZWR1SzRiWEVyS2JsS0JpN0RWOFZrTDEwQ2FjUGZEOThMYTBuTU5MVVI5bUNqa3ptZGlEUVNYRC1zdldwQXZM?oc=5", "source_name": "scanx.trade", "published_at": "2026-09-10T23:31:11+00:00", "source_names": ["scanx.trade"], "target_scope": "Takeda Pharmaceutical Co cuts FY26 adj EPS to $2.96, sales to $29.1B", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 13.4, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.011027, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "google_news", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": ["TAK.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "10 Sep 2026 23:31", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TAK.ARCHIVE", "provider_directional_mass": null}, {"url": "https://finance.yahoo.com/healthcare/articles/andy-plump-architect-takeda-r-112400854.html", "tier": "direct", "title": "Andy Plump, architect of Takeda\u2019s R&D overhaul, to retire next year", "topics": [], "summary": "", "age_days": 15.0, "is_stale": false, "provider": "yfinance", "providers": ["archive", "yfinance"], "sentiment": "neutral", "story_key": "a93dceb08cacdfb6eafbdb0fac0fc2d591c75def9c7d77a47a464ec4492ca1bb", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/healthcare/articles/andy-plump-architect-takeda-r-112400854.html", "source_name": "BioPharma Dive", "published_at": "2026-09-10T11:24:00+00:00", "source_names": ["BioPharma Dive"], "target_scope": "Andy Plump, architect of Takeda\u2019s R&D overhaul, to retire next year", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.6, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.000295, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["TAK", "TAK.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "10 Sep 2026 11:24", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TAK", "provider_directional_mass": null}, {"url": "https://finance.yahoo.com/healthcare/articles/trialbee-present-takeda-showcase-ai-130000891.html", "tier": "direct", "title": "Trialbee to Present with Takeda, Showcase AI for Clinical Sites, and Unveil AI-Powered Patient Screening at DPHARM 2026", "topics": ["AI", "Clinical Trials", "Healthcare", "Innovation", "Patient Recruitment"], "summary": "Trialbee continues to bring fresh innovation to clinical trials with its Honey Platform\u2122, demonstrating how AI is reshaping patient recruitment \u2013 and where it goes from here MALMO, Sweden & WILMINGTON, Del., September 09, 2026--(BUSINESS WIRE)--Trialbee, the global patient recruitment leader reimagining clinical trials with AI, will present alongside Takeda at DPHARM 2026 taking place September 15\u201316 in Boston. During the event, Trialbee will unveil AI patient screening in its Honey Platform\u2122, the next release on the Applied AI Recruitment roadmap it published earlier this year. Trialbee will ", "age_days": 15.9, "is_stale": false, "provider": "yfinance", "providers": ["yfinance"], "sentiment": "neutral", "story_key": "680a9ade94fa4eaa995debd74542ecba23315c809e91af61d2fbc488af423bc7", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "press_release", "source_link": "https://finance.yahoo.com/healthcare/articles/trialbee-present-takeda-showcase-ai-130000891.html", "source_name": "Business Wire", "published_at": "2026-09-09T13:00:00+00:00", "source_names": ["Business Wire"], "target_scope": "Trialbee to Present with Takeda, Showcase AI for Clinical Sites, and Unveil AI-Powered Patient Screening at DPHARM 2026 Trialbee continues to bring fresh innovation to clinical trials with its Honey Platform\u2122, demonstrating how AI is reshaping patient recruitment \u2013 and where it goes from here MALMO, Sweden & WILMINGTON, Del., September 09, 2026--(BUSINESS WIRE)--Trialbee, the global patient recruitment leader reimagining clinical trials with AI, will present alongside Takeda at DPHARM 2026 taking place September 15\u201316 in Boston.", "tone_signals": [], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.4, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "durable_archive": false, "evidence_weight": 0.0002, "influence_label": "None", "provider_symbol": "TAK.US", "relevance_score": 0.88388, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["TAK", "TAK.ARCHIVE", "TAK.US", "TKPHF.US"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 0, "published_display": "09 Sep 2026 13:00", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TAK", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxPWnVNVW5ZSmZVU1JGS3A3T1ZhVTlkeXVJMExSSzE3VTFlNEFsZmozS2xaaVhTMVlyQlFCZFZVZm1SMEdfM3VDbmdta05nVXVoZ0NzbTNZMVduQjJKdWljRFloNFV3aVNlTWtzcE5OY0luUjBVSVpQNFQ5dWZ3NnVwUzUwTC05YXhqWHNaZDhzNUhCOFp5SjBtRTZYMXB1MllhaDFiNnpXQXdlTGsyZWV1WVN6SjRKcTluSmpwUjdGc1BoSzYxZEJPMmlOczhsVlZQYXc?oc=5", "tier": "direct", "title": "Takeda Pharmaceutical Company L (TAK) Stock Analysis: Exploring a 22.66% Upside Potential", "topics": [], "summary": "", "age_days": 18.1, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "positive", "story_key": "6de734b370f1bd6a3926810ffd65e021832b2e49c90de09d90e9a2ebf11740cb", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxPWnVNVW5ZSmZVU1JGS3A3T1ZhVTlkeXVJMExSSzE3VTFlNEFsZmozS2xaaVhTMVlyQlFCZFZVZm1SMEdfM3VDbmdta05nVXVoZ0NzbTNZMVduQjJKdWljRFloNFV3aVNlTWtzcE5OY0luUjBVSVpQNFQ5dWZ3NnVwUzUwTC05YXhqWHNaZDhzNUhCOFp5SjBtRTZYMXB1MllhaDFiNnpXQXdlTGsyZWV1WVN6SjRKcTluSmpwUjdGc1BoSzYxZEJPMmlOczhsVlZQYXc?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-09-07T09:20:08+00:00", "source_names": ["DirectorsTalk Interviews"], "target_scope": "Takeda Pharmaceutical Company L (TAK) Stock Analysis: Exploring a 22.66% Upside Potential", "tone_signals": ["Positive valuation view"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.2, "sentiment_pct": 59, "evidence_basis": "headline_only", "evidence_share": 0.1, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.000176, "influence_label": "Low", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "google_news", "event_confidence": 35, "model_confidence": 0.542, "provider_symbols": ["TAK.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 32, "published_display": "07 Sep 2026 09:20", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "<0.1", "target_provider_symbol": "TAK.ARCHIVE", "provider_directional_mass": null}, {"url": "https://finance.yahoo.com/markets/stocks/articles/takeda-pharmaceutical-insider-sold-shares-072914824.html", "tier": "direct", "title": "Takeda Pharmaceutical Insider Sold Shares Worth $2,148,372, According to a Recent SEC Filing", "topics": [], "summary": "", "age_days": 21.2, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "negative", "story_key": "5d281d4f00a7e588c2d55187ef1d1b5e0ed65ac4c5b9ecdd9db5ed3f99ba9feb", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/markets/stocks/articles/takeda-pharmaceutical-insider-sold-shares-072914824.html", "source_name": "MT Newswires", "published_at": "2026-09-04T07:29:14+00:00", "source_names": ["MT Newswires"], "target_scope": "Takeda Pharmaceutical Insider Sold Shares Worth $2,148,372, According to a Recent SEC Filing", "tone_signals": ["Institutional or insider selling"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.1, "sentiment_pct": 42, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 5.8e-05, "influence_label": "Low", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "yfinance", "event_confidence": 35, "model_confidence": 0.539, "provider_symbols": ["TAK", "TAK.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 30, "published_display": "04 Sep 2026 07:29", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "<0.1", "target_provider_symbol": "TAK.ARCHIVE", "provider_directional_mass": null}, {"url": "https://www.marketbeat.com/stocks/NYSE/TAK/forecast", "tier": "direct", "title": "Takeda Pharmaceutical (TAK) Stock Forecast and Price Target 2026 $TAK", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Takeda Pharmaceutical (TAK) has a consensus \"Moderate Buy\" rating from Wall Street analysts, with 4 analysts covering the stock. The company recently received FDA approval for MIMRYLO and Japan approval for ORZEYFUL, expanding its therapeutic areas. Despite strong financial performance and product approvals, concerns exist regarding insider selling, regulatory challenges, a high P/E ratio, and potential new drug pricing deals.", "age_days": 22.8, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage", "archive"], "sentiment": "positive", "story_key": "6e73d0b58632a4315a9ad7646b645860ec7079751d1b5912cb179426525e454b", "event_type": "analyst", "tier_label": "Direct company coverage", "event_label": "Analyst action", "source_kind": "publisher", "source_link": "https://www.marketbeat.com/stocks/NYSE/TAK/forecast", "source_name": "MarketBeat", "published_at": "2026-09-02T15:30:54", "source_names": ["MarketBeat"], "target_scope": "Takeda Pharmaceutical (TAK) Stock Forecast and Price Target 2026 $TAK Takeda Pharmaceutical (TAK) has a consensus \"Moderate Buy\" rating from Wall Street analysts, with 4 analysts covering the stock.", "tone_signals": ["Fda Approval"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.5, "sentiment_pct": 59, "evidence_basis": "archived_article", "evidence_share": 0.2, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.000694, "influence_label": "Low", "provider_symbol": "", "relevance_score": 0.997012, "archive_provider": "", "event_confidence": 61, "model_confidence": 0.557, "provider_symbols": ["TAK", "TAK.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 32, "published_display": "02 Sep 2026 15:30", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0.2", "target_provider_symbol": "TAK", "provider_directional_mass": 0.2309}, {"url": "https://finance.yahoo.com/markets/stocks/articles/investors-undervaluing-takeda-pharmaceutical-co-134003598.html", "tier": "direct", "title": "Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?", "topics": ["Estimate Revisions", "Value Investing"], "summary": "While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies. Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use a variety of methods, including tried-and-true valuation metrics, to find these stocks. On", "age_days": 22.9, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "neutral", "story_key": "03308c2a0f223859ed3ef7e0d138acc1699629ab1438d8efc80ee5b524ed08bc", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/markets/stocks/articles/investors-undervaluing-takeda-pharmaceutical-co-134003598.html", "source_name": "Zacks", "published_at": "2026-09-02T13:40:03+00:00", "source_names": ["Zacks"], "target_scope": "Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?", "tone_signals": ["Positive valuation view"], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.0, "sentiment_pct": 55, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "durable_archive": false, "evidence_weight": 2.9e-05, "influence_label": "None", "provider_symbol": "TAK.US", "relevance_score": 0.88388, "archive_provider": "archive", "event_confidence": 35, "model_confidence": 0.548, "provider_symbols": ["PFE.BA", "TAK", "TAK.ARCHIVE", "TAK.US"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 0, "published_display": "02 Sep 2026 13:40", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TAK.ARCHIVE", "provider_directional_mass": null}, {"url": "https://finance.yahoo.com/healthcare/articles/takeda-weave-bio-collaborate-ai-095005482.html", "tier": "direct", "title": "Takeda and Weave Bio collaborate on AI-driven automation in drug development", "topics": [], "summary": "", "age_days": 23.1, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "positive", "story_key": "d864ead5acfac4f00f9077fcede1ffbff37d416db2023850d9c91cc6587e2baa", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/healthcare/articles/takeda-weave-bio-collaborate-ai-095005482.html", "source_name": "Pharmaceutical Technology", "published_at": "2026-09-02T09:50:05+00:00", "source_names": ["Pharmaceutical Technology"], "target_scope": "Takeda and Weave Bio collaborate on AI-driven automation in drug development", "tone_signals": ["Strategic partnership"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.0, "sentiment_pct": 59, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 3.1e-05, "influence_label": "Low", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "yfinance", "event_confidence": 35, "model_confidence": 0.541, "provider_symbols": ["TAK", "TAK.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 31, "published_display": "02 Sep 2026 09:50", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "<0.1", "target_provider_symbol": "TAK.ARCHIVE", "provider_directional_mass": null}, {"url": "https://finance.yahoo.com/healthcare/articles/weave-bio-announces-collaboration-takeda-130000815.html", "tier": "direct", "title": "Weave Bio Announces Collaboration with Takeda to Deploy AI-Native Regulatory Automation Across Key Drug Development Activities", "topics": ["AI", "Collaboration", "Drug Development", "Regulation"], "summary": "Co-authored IND submission preparation study results demonstrate ~97% reduction in time to first draft and 60% overall timeline compression SAN FRANCISCO, September 01, 2026--(BUSINESS WIRE)--Weave Bio, the leader in AI-native regulatory automation for drug development, today announced a collaboration with Takeda to deploy the Weave platform across 14 active programs in multiple global markets. The collaboration brings together Weave's AI capabilities and Takeda's regulatory expertise to support innovation in regulatory workflows. \"Regulatory communications are the most knowledge-intensive wor", "age_days": 23.9, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "positive", "story_key": "eeeff62b15dce850eba5005f37fcc1df2635e139fce8c1863f728111170d8768", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "press_release", "source_link": "https://finance.yahoo.com/healthcare/articles/weave-bio-announces-collaboration-takeda-130000815.html", "source_name": "Business Wire", "published_at": "2026-09-01T13:00:00+00:00", "source_names": ["Business Wire"], "target_scope": "Weave Bio Announces Collaboration with Takeda to Deploy AI-Native Regulatory Automation Across Key Drug Development Activities Co-authored IND submission preparation study results demonstrate ~97% reduction in time to first draft and 60% overall timeline compression SAN FRANCISCO, September 01, 2026--(BUSINESS WIRE)--Weave Bio, the leader in AI-native regulatory automation for drug development, today announced a collaboration with Takeda to deploy the Weave platform across 14 active programs in multiple global markets. The collaboration brings together Weave's AI capabilities and Takeda's regulatory expertise to support innovation in regulatory workflows.", "tone_signals": ["Strategic partnership"], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 3.6, "sentiment_pct": 61, "evidence_basis": "archived_article", "evidence_share": 1.9, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.005968, "influence_label": "Low", "provider_symbol": "TAK.US", "relevance_score": 0.88388, "archive_provider": "archive", "event_confidence": 53, "model_confidence": 0.638, "provider_symbols": ["TAK", "TAK.ARCHIVE", "TAK.US", "TKPHF.US"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 34, "published_display": "01 Sep 2026 13:00", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "1.9", "target_provider_symbol": "TAK.ARCHIVE", "provider_directional_mass": null}, {"url": "https://www.biopharmadive.com/news/fda-approve-mimrylo-takeda-protagonist-polycythemia-vera/829153", "tier": "direct", "title": "FDA OKs Takeda, Protagonist drug for rare blood cancer", "topics": ["Earnings", "Life Sciences"], "summary": "The FDA has approved Mimrylo, a drug developed by Takeda Pharmaceutical and Protagonist Therapeutics, for polycythemia vera, a rare blood cancer. Mimrylo is the first of its kind, mimicking the liver hormone hepcidin to control iron levels and red blood cell production, and has a broader-than-expected label. Analysts project its peak yearly sales could reach $2 billion or more for Takeda.", "age_days": 24.5, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage", "archive"], "sentiment": "neutral", "story_key": "7ec5f2529610c3df2c16364b7d585ca75dc8926692ec23e4ffd2b35af4e695e7", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.biopharmadive.com/news/fda-approve-mimrylo-takeda-protagonist-polycythemia-vera/829153", "source_name": "BioPharma Dive", "published_at": "2026-08-31T23:32:24", "source_names": ["BioPharma Dive"], "target_scope": "FDA OKs Takeda, Protagonist drug for rare blood cancer The FDA has approved Mimrylo, a drug developed by Takeda Pharmaceutical and Protagonist Therapeutics, for polycythemia vera, a rare blood cancer. Analysts project its peak yearly sales could reach $2 billion or more for Takeda.", "tone_signals": ["Contract or approval won"], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 3.4, "sentiment_pct": 55, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.003827, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.533, "provider_symbols": ["INCY", "PTGX", "TAK", "TAK.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 0, "published_display": "31 Aug 2026 23:32", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TAK", "provider_directional_mass": 0.4746}, {"url": "https://finance.yahoo.com/healthcare/articles/market-chatter-takeda-other-biotech-195856162.html", "tier": "direct", "title": "Update: Market Chatter: Takeda, Other Biotech Firms to Announce New Drug Pricing Deals With White House", "topics": [], "summary": "", "age_days": 24.6, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "neutral", "story_key": "26baba686f2a57e768f686806f0a67ffe71893a29763d4c7edbb914bc3de4cda", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/healthcare/articles/market-chatter-takeda-other-biotech-195856162.html", "source_name": "MT Newswires", "published_at": "2026-08-31T19:58:56+00:00", "source_names": ["MT Newswires"], "target_scope": "Update: Market Chatter: Takeda, Other Biotech Firms to Announce New Drug Pricing Deals With White House", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.0, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 1e-05, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "yfinance", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["BAYN.DE", "TAK", "TAK.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "31 Aug 2026 19:58", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TAK.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTE9EamZqX1JNRjVScTFyOEs3MkdHejNlMWNXZlRLeG1mMjJLOF9nUFNZMUtVeEpQc3VzMGxSWWxaZjkxMDdMQ2M0VEtjZTlPWHY3?oc=5", "tier": "direct", "title": "Takeda Pharmaceutical Company Limited (TAK) stock price, news, quote and history", "topics": [], "summary": "", "age_days": 24.8, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "neutral", "story_key": "7bb5153fea0014ebce5956d705c2d26c137f006bd559b4ce9ab67daf56023aa3", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "aggregator", "source_link": "https://news.google.com/rss/articles/CBMiUEFVX3lxTE9EamZqX1JNRjVScTFyOEs3MkdHejNlMWNXZlRLeG1mMjJLOF9nUFNZMUtVeEpQc3VzMGxSWWxaZjkxMDdMQ2M0VEtjZTlPWHY3?oc=5", "source_name": "Market source", "published_at": "2026-08-31T17:21:45+00:00", "source_names": ["Market source"], "target_scope": "Takeda Pharmaceutical Company Limited (TAK) stock price, news, quote and history", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.0, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 9e-06, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "google_news", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["TAK.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "31 Aug 2026 17:21", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TAK.ARCHIVE", "provider_directional_mass": null}, {"url": "https://finance.yahoo.com/healthcare/articles/takeda-secures-fda-approval-first-163813261.html", "tier": "direct", "title": "Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug", "topics": ["Biotech", "Clinical Trials", "Fda Approval"], "summary": "On Friday, the U.S. Food and Drug Administration (FDA) approvedTakeda Pharmaceutical Co. Ltd.'s (NYSE:TAK) MIMRYLO (rusfertide) for polycythemia vera, a type of blood cancer. How MIMRYLO Combats Polycythemia Vera Polycythemia vera forces the human body to overproduce red blood cells. This harmful overproduction dramatically increases blood thickness. Increased viscosity places patients at high risk for life-threatening thrombotic events, which include severe complications like strokes, pulmonary embolisms, and deep vein thrombosis. To prevent these severe health events, medical providers focus", "age_days": 24.8, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "positive", "story_key": "4f35e5f170a686d40ad7d549288ca1d840ba68d2b1c842e8d02e223bf1e20023", "event_type": "regulatory", "tier_label": "Direct company coverage", "event_label": "Regulatory and legal", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/healthcare/articles/takeda-secures-fda-approval-first-163813261.html", "source_name": "Benzinga", "published_at": "2026-08-31T16:38:13+00:00", "source_names": ["Benzinga"], "target_scope": "Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug Food and Drug Administration (FDA) approvedTakeda Pharmaceutical Co. Ltd.'s (NYSE:TAK) MIMRYLO (rusfertide) for polycythemia vera, a type of blood cancer.", "tone_signals": ["Contract or approval won"], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 8.6, "sentiment_pct": 67, "evidence_basis": "archived_article", "evidence_share": 5.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.015573, "influence_label": "Medium", "provider_symbol": "TAK.US", "relevance_score": 0.78, "archive_provider": "archive", "event_confidence": 53, "model_confidence": 0.564, "provider_symbols": ["PFE.DU", "PFE.MU", "PTGX.US", "TAK", "TAK.ARCHIVE", "TAK.US"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 41, "published_display": "31 Aug 2026 16:38", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "5", "target_provider_symbol": "TAK.ARCHIVE", "provider_directional_mass": null}, {"url": "https://www.bizjournals.com/boston/news/2026/08/28/takeda-wins-approval-for-two-drugs-in-one-month.html", "tier": "direct", "title": "Takeda wins second drug approval in August as it eyes return to growth", "topics": ["Earnings", "Life Sciences"], "summary": "Takeda secured two drug approvals in August for blood cancer and narcolepsy. These approvals are crucial as the biotech company navigates short-term generic competition and aims to achieve sustainable revenue and profit growth in fiscal 2025. The company is also preparing to move into a new global R&D center in Cambridge.", "age_days": 25.1, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage", "archive"], "sentiment": "positive", "story_key": "7f61ead17039a80a9d815edb8cb798a8e97655a8f86e01e98067992d838b24d5", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.bizjournals.com/boston/news/2026/08/28/takeda-wins-approval-for-two-drugs-in-one-month.html", "source_name": "The Business Journals", "published_at": "2026-08-31T10:02:45", "source_names": ["The Business Journals"], "target_scope": "Takeda wins second drug approval in August as it eyes return to growth Takeda secured two drug approvals in August for blood cancer and narcolepsy.", "tone_signals": ["Contract or approval won"], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 3.1, "sentiment_pct": 67, "evidence_basis": "archived_article", "evidence_share": 1.6, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.004885, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.564, "provider_symbols": ["BSX", "MRNA", "TAK", "TAK.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 40, "published_display": "31 Aug 2026 10:02", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "1.6", "target_provider_symbol": "TAK", "provider_directional_mass": 0.605}, {"url": "https://seekingalpha.com/news/4638031-takeda-gains-approval-rusfertide-polycythemia-vera?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "tier": "direct", "title": "Takeda gains approval of rusfertide for polycythemia vera", "topics": ["Blood Cancer", "Clinical Trials", "Fda Approval", "Healthcare", "Pharma"], "summary": "[Polycythemia vera, artwork] Dr_Microbe/iStock via Getty Images * The US FDA approved Takeda Pharmaceutical's (TAK [https://seekingalpha.com/symbol/TAK]) Mimrylo (rusfertide), a first-in-class treatment for the rare blood disorder polycythemia vera. * Mimrylo works by mimicking hepcidin, a hormone that naturally regulates iron. The drug limits the iron in the body to make new red blood cells, cutting their their overproduction and mainiaining healthy red blood cell levels. * Approval was based [https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-its-kind-polycythemia-ve", "age_days": 27.6, "is_stale": false, "provider": "eodhd", "providers": ["eodhd"], "sentiment": "positive", "story_key": "3bfa88376c579bec809f68a7d855e861e1598061612e286db2563007d14e79f4", "event_type": "regulatory", "tier_label": "Direct company coverage", "event_label": "Regulatory and legal", "source_kind": "publisher", "source_link": "https://seekingalpha.com/news/4638031-takeda-gains-approval-rusfertide-polycythemia-vera?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_name": "seekingalpha.com", "published_at": "2026-08-28T21:44:35+00:00", "source_names": ["seekingalpha.com"], "target_scope": "Takeda gains approval of rusfertide for polycythemia vera [Polycythemia vera, artwork] Dr_Microbe/iStock via Getty Images * The US FDA approved Takeda Pharmaceutical's (TAK [https://seekingalpha.com/symbol/TAK]) Mimrylo (rusfertide), a first-in-class treatment for the rare blood disorder polycythemia vera.", "tone_signals": ["Contract or approval won"], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 6.5, "sentiment_pct": 62, "evidence_basis": "archived_article", "evidence_share": 3.4, "score_included": true, "duplicate_count": 2, "durable_archive": false, "evidence_weight": 0.010582, "influence_label": "Low", "provider_symbol": "TAK.US", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.564, "provider_symbols": ["TAK", "TAK.ARCHIVE", "TAK.US", "TKPHF.US"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 35, "published_display": "28 Aug 2026 21:44", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "3.4", "target_provider_symbol": "TAK.US", "provider_directional_mass": 0.166}, {"url": "https://www.fiercepharma.com/pharma/takeda-bolsters-blood-cancer-portfolio-fda-approval-mimrylo-polycythemia-vera", "tier": "direct", "title": "Takeda bolsters blood cancer portfolio with FDA nod for Mimrylo in polycythemia vera", "topics": ["Life Sciences"], "summary": "Takeda has received FDA approval for Mimrylo (rusfertide) to treat polycythemia vera, a rare blood cancer. Mimrylo is a first-in-class drug that mimics hepcidin, regulating iron and thereby curtailing the overproduction of red blood cells. This approval marks another significant regulatory win for CEO Julie Kim and is expected to contribute to Takeda's future growth alongside two other new medicines.", "age_days": 27.6, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage", "archive"], "sentiment": "positive", "story_key": "5f7d8f1fe694009c6c29a89359752bb6977995b9fc7355da59f5908392e59bcd", "event_type": "regulatory", "tier_label": "Direct company coverage", "event_label": "Regulatory and legal", "source_kind": "publisher", "source_link": "https://www.fiercepharma.com/pharma/takeda-bolsters-blood-cancer-portfolio-fda-approval-mimrylo-polycythemia-vera", "source_name": "Fierce Pharma", "published_at": "2026-08-28T22:04:00", "source_names": ["Fierce Pharma"], "target_scope": "Takeda bolsters blood cancer portfolio with FDA nod for Mimrylo in polycythemia vera Takeda has received FDA approval for Mimrylo (rusfertide) to treat polycythemia vera, a rare blood cancer. This approval marks another significant regulatory win for CEO Julie Kim and is expected to contribute to Takeda's future growth alongside two other new medicines.", "tone_signals": ["Fda Approval"], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 6.5, "sentiment_pct": 57, "evidence_basis": "archived_article", "evidence_share": 2.5, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.007596, "influence_label": "Low", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 61, "model_confidence": 0.536, "provider_symbols": ["BMY", "INCY", "TAK", "TAK.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 29, "published_display": "28 Aug 2026 22:04", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "2.5", "target_provider_symbol": "TAK", "provider_directional_mass": 0.0258}, {"url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE9VNy1kRFNkNE9pdVRfV29fTEVONXpuajBWLThyYWxVRURfb2NjaG55Vzg5QkdvaHg1Rnpld2lvZTNpdHFXbWdnNi1JQmtVbFNpeXVYbUpya0xSTktlTS1wMmZ6bXBraDRSREVaVg?oc=5", "tier": "direct", "title": "TAK|Takeda Pharmaceutical Co Ltd|Price:18.030|", "topics": [], "summary": "", "age_days": 28.2, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "neutral", "story_key": "2a6e75bbe90f4bdaf517cd1c528c8879e16d919ab7166b1778b0dcfe9751aab1", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMibEFVX3lxTE9VNy1kRFNkNE9pdVRfV29fTEVONXpuajBWLThyYWxVRURfb2NjaG55Vzg5QkdvaHg1Rnpld2lvZTNpdHFXbWdnNi1JQmtVbFNpeXVYbUpya0xSTktlTS1wMmZ6bXBraDRSREVaVg?oc=5", "source_name": "tradingkey.com", "published_at": "2026-08-28T07:00:00+00:00", "source_names": ["tradingkey.com"], "target_scope": "TAK|Takeda Pharmaceutical Co Ltd|Price:18.030|", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.0, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 3e-06, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "google_news", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["TAK.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "28 Aug 2026 07:00", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TAK.ARCHIVE", "provider_directional_mass": null}], "industry": [], "sector": []}, "detail_intelligence": {"headline": "Early balanced news score", "summary": "39 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.", "status": "provisional", "metrics": [{"label": "News score", "value": 54, "display": "54", "tone": "neutral", "note": "Early balanced news score"}, {"label": "Confidence", "value": 27, "display": "27", "tone": "negative", "note": "thin evidence"}, {"label": "Company news", "value": 97, "display": "97%", "tone": "positive", "note": "39 company stories"}, {"label": "Story agreement", "value": 88, "display": "88", "tone": "positive", "note": "12/100 difference"}], "confidence_drivers": [{"label": "Amount of evidence", "value": 6, "note": "0.309 after freshness weighting"}, {"label": "Source breadth", "value": 100, "note": "11 independent publishers"}, {"label": "Company relevance", "value": 97, "note": "share tied directly to this company"}, {"label": "Freshness", "value": 33, "note": "recency-weighted evidence"}, {"label": "Agreement", "value": 88, "note": "how closely stories agree"}, {"label": "Publisher mix", "value": 63, "note": "less reliance on one publisher"}], "freshness": 33, "source_independence": 63, "timeline": [{"date": "2026-08-29", "label": "29 Aug", "count": 0, "score": null, "tone": "neutral", "x": 42.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-30", "label": "30 Aug", "count": 0, "score": null, "tone": "neutral", "x": 73.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-31", "label": "31 Aug", "count": 5, "score": 65, "tone": "positive", "x": 105.2, "y": 107.7, "volume_height": 43.3, "volume_y": 222.7}, {"date": "2026-09-01", "label": "01 Sep", "count": 1, "score": 61, "tone": "positive", "x": 136.8, "y": 115.0, "volume_height": 8.7, "volume_y": 257.3}, {"date": "2026-09-02", "label": "02 Sep", "count": 3, "score": 59, "tone": "positive", "x": 168.3, "y": 118.6, "volume_height": 26.0, "volume_y": 240.0}, {"date": "2026-09-03", "label": "03 Sep", "count": 0, "score": null, "tone": "neutral", "x": 199.9, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-04", "label": "04 Sep", "count": 1, "score": 42, "tone": "negative", "x": 231.5, "y": 149.6, "volume_height": 8.7, "volume_y": 257.3}, {"date": "2026-09-05", "label": "05 Sep", "count": 0, "score": null, "tone": "neutral", "x": 263.1, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-06", "label": "06 Sep", "count": 0, "score": null, "tone": "neutral", "x": 294.7, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-07", "label": "07 Sep", "count": 1, "score": 59, "tone": "positive", "x": 326.3, "y": 118.6, "volume_height": 8.7, "volume_y": 257.3}, {"date": "2026-09-08", "label": "08 Sep", "count": 0, "score": null, "tone": "neutral", "x": 357.9, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-09", "label": "09 Sep", "count": 1, "score": 50, "tone": "neutral", "x": 389.4, "y": 135.0, "volume_height": 8.7, "volume_y": 257.3}, {"date": "2026-09-10", "label": "10 Sep", "count": 2, "score": 50, "tone": "neutral", "x": 421.0, "y": 135.0, "volume_height": 17.3, "volume_y": 248.7}, {"date": "2026-09-11", "label": "11 Sep", "count": 2, "score": 50, "tone": "neutral", "x": 452.6, "y": 135.0, "volume_height": 17.3, "volume_y": 248.7}, {"date": "2026-09-12", "label": "12 Sep", "count": 0, "score": null, "tone": "neutral", "x": 484.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-13", "label": "13 Sep", "count": 0, "score": null, "tone": "neutral", "x": 515.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-14", "label": "14 Sep", "count": 2, "score": 50, "tone": "neutral", "x": 547.4, "y": 135.0, "volume_height": 17.3, "volume_y": 248.7}, {"date": "2026-09-15", "label": "15 Sep", "count": 0, "score": null, "tone": "neutral", "x": 579.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-16", "label": "16 Sep", "count": 1, "score": 50, "tone": "neutral", "x": 610.6, "y": 135.0, "volume_height": 8.7, "volume_y": 257.3}, {"date": "2026-09-17", "label": "17 Sep", "count": 1, "score": 50, "tone": "neutral", "x": 642.1, "y": 135.0, "volume_height": 8.7, "volume_y": 257.3}, {"date": "2026-09-18", "label": "18 Sep", "count": 6, "score": 48, "tone": "neutral", "x": 673.7, "y": 138.6, "volume_height": 52.0, "volume_y": 214.0}, {"date": "2026-09-19", "label": "19 Sep", "count": 2, "score": 50, "tone": "neutral", "x": 705.3, "y": 135.0, "volume_height": 17.3, "volume_y": 248.7}, {"date": "2026-09-20", "label": "20 Sep", "count": 1, "score": 50, "tone": "neutral", "x": 736.9, "y": 135.0, "volume_height": 8.7, "volume_y": 257.3}, {"date": "2026-09-21", "label": "21 Sep", "count": 1, "score": 76, "tone": "positive", "x": 768.5, "y": 87.7, "volume_height": 8.7, "volume_y": 257.3}, {"date": "2026-09-22", "label": "22 Sep", "count": 3, "score": 52, "tone": "neutral", "x": 800.1, "y": 131.4, "volume_height": 26.0, "volume_y": 240.0}, {"date": "2026-09-23", "label": "23 Sep", "count": 2, "score": 54, "tone": "neutral", "x": 831.7, "y": 127.7, "volume_height": 17.3, "volume_y": 248.7}, {"date": "2026-09-24", "label": "24 Sep", "count": 1, "score": 50, "tone": "neutral", "x": 863.2, "y": 135.0, "volume_height": 8.7, "volume_y": 257.3}, {"date": "2026-09-25", "label": "25 Sep", "count": 0, "score": null, "tone": "neutral", "x": 894.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-26", "label": "26 Sep", "count": 0, "score": null, "tone": "neutral", "x": 926.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-27", "label": "27 Sep", "count": 0, "score": null, "tone": "neutral", "x": 958.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}], "timeline_points": "105.2,107.7 136.8,115.0 168.3,118.6 231.5,149.6 326.3,118.6 389.4,135.0 421.0,135.0 452.6,135.0 547.4,135.0 610.6,135.0 642.1,135.0 673.7,138.6 705.3,135.0 736.9,135.0 768.5,87.7 800.1,131.4 831.7,127.7 863.2,135.0", "timeline_has_signal": true, "timeline_start": "29 Aug", "timeline_mid": "13 Sep", "timeline_end": "27 Sep", "momentum": {"label": "Tentative cooling", "tone": "neutral", "recent_score": 50, "prior_score": 62, "delta": -12, "recent_count": 1, "prior_count": 6, "volume_delta": -5, "reliable": false, "reliability_note": "Thin comparison; direction is not yet confirmed"}, "early_change": {"label": "No new story in 24 hours", "tone": "neutral", "latest_score": null, "baseline_score": 60, "delta": null, "latest_count": 0, "baseline_count": 8, "confirmed": false, "note": "A comparison needs current and earlier-week company news"}, "freshness_buckets": [{"label": "Last 24 hours", "count": 0, "share": 0}, {"label": "1 to 3 days", "count": 1, "share": 3}, {"label": "4 to 7 days", "count": 7, "share": 18}, {"label": "8 to 14 days", "count": 12, "share": 31}, {"label": "15 to 21 days", "count": 6, "share": 15}, {"label": "22 to 30 days", "count": 13, "share": 33}], "source_profile": [{"label": "Business Wire", "count": 4, "share": 10, "score": 52, "tone": "neutral"}, {"label": "MT Newswires", "count": 4, "share": 10, "score": 50, "tone": "neutral"}, {"label": "DirectorsTalk Interviews", "count": 2, "share": 5, "score": 76, "tone": "positive"}, {"label": "MarketBeat", "count": 2, "share": 5, "score": 56, "tone": "neutral"}, {"label": "BioPharma Dive", "count": 2, "share": 5, "score": 55, "tone": "neutral"}, {"label": "Benzinga", "count": 2, "share": 5, "score": 54, "tone": "neutral"}, {"label": "scanx.trade", "count": 2, "share": 5, "score": 50, "tone": "neutral"}], "event_profile": [{"label": "Market update", "count": 18, "share": 46, "score": 52, "tone": "neutral"}, {"label": "Earnings", "count": 11, "share": 28, "score": 60, "tone": "positive"}, {"label": "Regulatory and legal", "count": 5, "share": 13, "score": 54, "tone": "neutral"}, {"label": "Deals and strategy", "count": 4, "share": 10, "score": 50, "tone": "neutral"}, {"label": "Analyst action", "count": 1, "share": 3, "score": 59, "tone": "positive"}], "topics": [{"label": "Life Sciences", "count": 17, "share": 44}, {"label": "Earnings", "count": 10, "share": 26}, {"label": "Clinical Trials", "count": 6, "share": 15}, {"label": "Financial Markets", "count": 5, "share": 13}, {"label": "Fda Approval", "count": 4, "share": 10}, {"label": "Pharma", "count": 3, "share": 8}, {"label": "Healthcare", "count": 3, "share": 8}, {"label": "Mergers And Acquisitions", "count": 2, "share": 5}, {"label": "Finance", "count": 2, "share": 5}, {"label": "Biotech", "count": 2, "share": 5}], "supporting": [{"label": "Direct evidence", "text": "39 current stories are mapped specifically to TAK."}, {"label": "Source breadth", "text": "The score uses 11 publishers rather than depending on one outlet."}], "tempering": [{"label": "Too little evidence", "text": "The stories agree, but freshness-weighted evidence is only 0.309."}, {"label": "Confidence", "text": "Confidence is 27/100, below the threshold for a firm score."}], "supporting_heading": "What supports the score", "tempering_heading": "What limits the score", "latest_observation": {"url": "https://www.takeda.com/our-impact/our-stories/climate-ready-healthcare-global-csr-programs", "tier": "direct", "title": "Climate-ready healthcare: Our 2026 global CSR programs", "topics": ["Life Sciences", "Economy Macro"], "summary": "Takeda announced its 2026 global Corporate Social Responsibility (CSR) programs, committing USD 22.2 million to four new multi-year projects aimed at strengthening climate-resilient health systems worldwide. These initiatives, chosen by Takeda employees, will support organizations like Corus International, Humanity & Inclusion \u2013 Handicap International, Kwame Nkrumah University of Science and Technology, and Terre des hommes Foundation in countries such as Nepal, Honduras, Peru, Ghana, Egypt, and Lebanon. The programs focus on areas including early warning systems, resilient service delivery, workforce capacity building, and greener practices to address the widespread impact of climate change on global health outcomes.", "age_days": 1.1, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.takeda.com/our-impact/our-stories/climate-ready-healthcare-global-csr-programs", "source_name": "Takeda Pharmaceuticals", "published_at": "2026-09-24T09:47:40", "tone_signals": ["Negative financial language"], "company_focus": 0.86, "freshness_pct": 69.0, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.041109, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 86, "evidence_strength": 0, "published_display": "24 Sep 2026 09:47", "direction_included": false, "company_focus_label": "Company discussed", "source_link_is_lookup": false, "evidence_share_display": "0"}, "article_count": 39, "updated_at": "2026-09-25T11:26:44.805560+00:00"}, "price_sentiment_path": {"available": true, "price_points": [{"x": 42.0, "y": 63.4, "label": "03 Apr 2026", "close": 18.74, "index": 100.0}, {"x": 78.4, "y": 93.0, "label": "10 Apr 2026", "close": 18.08, "index": 96.5}, {"x": 114.9, "y": 104.7, "label": "17 Apr 2026", "close": 17.82, "index": 95.1}, {"x": 151.3, "y": 158.0, "label": "24 Apr 2026", "close": 16.63, "index": 88.7}, {"x": 187.7, "y": 158.5, "label": "01 May 2026", "close": 16.62, "index": 88.7}, {"x": 224.2, "y": 165.6, "label": "08 May 2026", "close": 16.46, "index": 87.8}, {"x": 260.6, "y": 158.9, "label": "15 May 2026", "close": 16.61, "index": 88.6}, {"x": 297.0, "y": 175.1, "label": "22 May 2026", "close": 16.25, "index": 86.7}, {"x": 333.5, "y": 188.1, "label": "29 May 2026", "close": 15.96, "index": 85.2}, {"x": 369.9, "y": 204.2, "label": "05 Jun 2026", "close": 15.6, "index": 83.2}, {"x": 406.3, "y": 190.3, "label": "12 Jun 2026", "close": 15.91, "index": 84.9}, {"x": 442.8, "y": 202.8, "label": "19 Jun 2026", "close": 15.63, "index": 83.4}, {"x": 479.2, "y": 190.3, "label": "26 Jun 2026", "close": 15.91, "index": 84.9}, {"x": 515.6, "y": 151.7, "label": "03 Jul 2026", "close": 16.77, "index": 89.5}, {"x": 552.0, "y": 161.2, "label": "10 Jul 2026", "close": 16.56, "index": 88.4}, {"x": 588.5, "y": 134.7, "label": "17 Jul 2026", "close": 17.15, "index": 91.5}, {"x": 624.9, "y": 130.7, "label": "24 Jul 2026", "close": 17.24, "index": 92.0}, {"x": 661.3, "y": 137.4, "label": "31 Jul 2026", "close": 17.09, "index": 91.2}, {"x": 697.8, "y": 121.3, "label": "07 Aug 2026", "close": 17.45, "index": 93.1}, {"x": 734.2, "y": 113.2, "label": "14 Aug 2026", "close": 17.63, "index": 94.1}, {"x": 770.6, "y": 88.5, "label": "21 Aug 2026", "close": 18.18, "index": 97.0}, {"x": 807.1, "y": 95.3, "label": "28 Aug 2026", "close": 18.03, "index": 96.2}, {"x": 843.5, "y": 76.4, "label": "04 Sep 2026", "close": 18.45, "index": 98.5}, {"x": 879.9, "y": 84.9, "label": "11 Sep 2026", "close": 18.26, "index": 97.4}, {"x": 916.4, "y": 55.8, "label": "18 Sep 2026", "close": 18.91, "index": 100.9}, {"x": 952.8, "y": 58.0, "label": "25 Sep 2026", "close": 18.86, "index": 100.6}], "sentiment_points": [{"at": "2026-04-03T23:59:59.999Z", "date": "2026-04-03", "label": "03 Apr 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 0, "stories": 1, "close": 18.74, "price_change": null, "x": 47.2, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-04-10T23:59:59.999Z", "date": "2026-04-10", "label": "10 Apr 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 0, "stories": 1, "close": 18.08, "price_change": -3.5, "x": 83.6, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-04-17T23:59:59.999Z", "date": "2026-04-17", "label": "17 Apr 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 0, "stories": 2, "close": 17.82, "price_change": -1.4, "x": 120.1, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-04-24T23:59:59.999Z", "date": "2026-04-24", "label": "24 Apr 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 0, "stories": 1, "close": 16.63, "price_change": -6.7, "x": 156.5, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-05-01T23:59:59.999Z", "date": "2026-05-01", "label": "01 May 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 0, "stories": 2, "close": 16.62, "price_change": -0.1, "x": 192.9, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-05-08T23:59:59.999Z", "date": "2026-05-08", "label": "08 May 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 0, "stories": 2, "close": 16.46, "price_change": -1.0, "x": 229.4, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-05-15T23:59:59.999Z", "date": "2026-05-15", "label": "15 May 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 0, "stories": 3, "close": 16.61, "price_change": 0.9, "x": 265.8, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-05-22T23:59:59.999Z", "date": "2026-05-22", "label": "22 May 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 0, "stories": 3, "close": 16.25, "price_change": -2.2, "x": 302.2, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-05-29T23:59:59.999Z", "date": "2026-05-29", "label": "29 May 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 0, "stories": 4, "close": 15.96, "price_change": -1.8, "x": 338.7, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-06-05T23:59:59.999Z", "date": "2026-06-05", "label": "05 Jun 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 0, "stories": 3, "close": 15.6, "price_change": -2.3, "x": 375.1, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-06-12T23:59:59.999Z", "date": "2026-06-12", "label": "12 Jun 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 0, "stories": 1, "close": 15.91, "price_change": 2.0, "x": 411.5, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-06-19T23:59:59.999Z", "date": "2026-06-19", "label": "19 Jun 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 0, "stories": 1, "close": 15.63, "price_change": -1.8, "x": 448.0, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-06-26T23:59:59.999Z", "date": "2026-06-26", "label": "26 Jun 2026", "score": 50, "tone": "neutral", "raw_score": 59, "confidence": 19, "stories": 7, "close": 15.91, "price_change": 1.8, "x": 484.4, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-03T23:59:59.999Z", "date": "2026-07-03", "label": "03 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 57, "confidence": 19, "stories": 11, "close": 16.77, "price_change": 5.4, "x": 520.8, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-07-10T23:59:59.999Z", "date": "2026-07-10", "label": "10 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 59, "confidence": 15, "stories": 16, "close": 16.56, "price_change": -1.3, "x": 557.2, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-07-17T23:59:59.999Z", "date": "2026-07-17", "label": "17 Jul 2026", "score": 48, "tone": "neutral", "raw_score": 43, "confidence": 34, "stories": 22, "close": 17.15, "price_change": 3.6, "x": 593.7, "y": 133.7, "show_label": false, "label_y": 123.69999999999999}, {"at": "2026-07-24T23:59:59.999Z", "date": "2026-07-24", "label": "24 Jul 2026", "score": 52, "tone": "neutral", "raw_score": 56, "confidence": 34, "stories": 31, "close": 17.24, "price_change": 0.5, "x": 630.1, "y": 126.3, "show_label": true, "label_y": 116.3}, {"at": "2026-07-31T23:59:59.999Z", "date": "2026-07-31", "label": "31 Jul 2026", "score": 54, "tone": "neutral", "raw_score": 58, "confidence": 39, "stories": 51, "close": 17.09, "price_change": -0.9, "x": 666.5, "y": 122.6, "show_label": false, "label_y": 112.6}, {"at": "2026-08-07T23:59:59.999Z", "date": "2026-08-07", "label": "07 Aug 2026", "score": 60, "tone": "positive", "raw_score": 66, "confidence": 45, "stories": 61, "close": 17.45, "price_change": 2.1, "x": 703.0, "y": 111.6, "show_label": false, "label_y": 101.6}, {"at": "2026-08-14T23:59:59.999Z", "date": "2026-08-14", "label": "14 Aug 2026", "score": 55, "tone": "neutral", "raw_score": 59, "confidence": 42, "stories": 87, "close": 17.63, "price_change": 1.0, "x": 739.4, "y": 120.8, "show_label": false, "label_y": 110.8}, {"at": "2026-08-21T23:59:59.999Z", "date": "2026-08-21", "label": "21 Aug 2026", "score": 58, "tone": "positive", "raw_score": 65, "confidence": 41, "stories": 90, "close": 18.18, "price_change": 3.1, "x": 775.8, "y": 115.3, "show_label": true, "label_y": 105.3}, {"at": "2026-08-28T23:59:59.999Z", "date": "2026-08-28", "label": "28 Aug 2026", "score": 58, "tone": "positive", "raw_score": 65, "confidence": 40, "stories": 76, "close": 18.03, "price_change": -0.8, "x": 812.3, "y": 115.3, "show_label": false, "label_y": 105.3}, {"at": "2026-09-04T23:59:59.999Z", "date": "2026-09-04", "label": "04 Sep 2026", "score": 57, "tone": "neutral", "raw_score": 63, "confidence": 37, "stories": 70, "close": 18.45, "price_change": 2.3, "x": 848.7, "y": 117.1, "show_label": false, "label_y": 107.1}, {"at": "2026-09-11T23:59:59.999Z", "date": "2026-09-11", "label": "11 Sep 2026", "score": 54, "tone": "neutral", "raw_score": 65, "confidence": 25, "stories": 52, "close": 18.26, "price_change": -1.0, "x": 885.1, "y": 122.6, "show_label": false, "label_y": 112.6}, {"at": "2026-09-18T23:59:59.999Z", "date": "2026-09-18", "label": "18 Sep 2026", "score": 51, "tone": "neutral", "raw_score": 56, "confidence": 26, "stories": 38, "close": 18.91, "price_change": 3.6, "x": 921.6, "y": 128.2, "show_label": true, "label_y": 118.19999999999999}, {"at": "2026-09-25T23:59:59.999Z", "date": "2026-09-25", "label": "25 Sep 2026", "score": 53, "tone": "neutral", "raw_score": 65, "confidence": 25, "stories": 39, "close": 18.86, "price_change": -0.3, "x": 958.0, "y": 124.5, "show_label": true, "label_y": 114.5}], "price_path": "42.0,63.4 78.4,93.0 114.9,104.7 151.3,158.0 187.7,158.5 224.2,165.6 260.6,158.9 297.0,175.1 333.5,188.1 369.9,204.2 406.3,190.3 442.8,202.8 479.2,190.3 515.6,151.7 552.0,161.2 588.5,134.7 624.9,130.7 661.3,137.4 697.8,121.3 734.2,113.2 770.6,88.5 807.1,95.3 843.5,76.4 879.9,84.9 916.4,55.8 952.8,58.0", "sentiment_path": "47.2,130.0 83.6,130.0 120.1,130.0 156.5,130.0 192.9,130.0 229.4,130.0 265.8,130.0 302.2,130.0 338.7,130.0 375.1,130.0 411.5,130.0 448.0,130.0 484.4,130.0 520.8,130.0 557.2,130.0 593.7,133.7 630.1,126.3 666.5,122.6 703.0,111.6 739.4,120.8 775.8,115.3 812.3,115.3 848.7,117.1 885.1,122.6 921.6,128.2 958.0,124.5", "score_version": "evidence-v10", "price_change": 0.6, "sentiment_change": 3, "recent_pairs": [{"at": "2026-09-25T23:59:59.999Z", "date": "2026-09-25", "label": "25 Sep 2026", "score": 53, "tone": "neutral", "raw_score": 65, "confidence": 25, "stories": 39, "close": 18.86, "price_change": -0.3, "x": 958.0, "y": 124.5, "show_label": true, "label_y": 114.5}, {"at": "2026-09-18T23:59:59.999Z", "date": "2026-09-18", "label": "18 Sep 2026", "score": 51, "tone": "neutral", "raw_score": 56, "confidence": 26, "stories": 38, "close": 18.91, "price_change": 3.6, "x": 921.6, "y": 128.2, "show_label": true, "label_y": 118.19999999999999}, {"at": "2026-09-11T23:59:59.999Z", "date": "2026-09-11", "label": "11 Sep 2026", "score": 54, "tone": "neutral", "raw_score": 65, "confidence": 25, "stories": 52, "close": 18.26, "price_change": -1.0, "x": 885.1, "y": 122.6, "show_label": false, "label_y": 112.6}, {"at": "2026-09-04T23:59:59.999Z", "date": "2026-09-04", "label": "04 Sep 2026", "score": 57, "tone": "neutral", "raw_score": 63, "confidence": 37, "stories": 70, "close": 18.45, "price_change": 2.3, "x": 848.7, "y": 117.1, "show_label": false, "label_y": 107.1}, {"at": "2026-08-28T23:59:59.999Z", "date": "2026-08-28", "label": "28 Aug 2026", "score": 58, "tone": "positive", "raw_score": 65, "confidence": 40, "stories": 76, "close": 18.03, "price_change": -0.8, "x": 812.3, "y": 115.3, "show_label": false, "label_y": 105.3}, {"at": "2026-08-21T23:59:59.999Z", "date": "2026-08-21", "label": "21 Aug 2026", "score": 58, "tone": "positive", "raw_score": 65, "confidence": 41, "stories": 90, "close": 18.18, "price_change": 3.1, "x": 775.8, "y": 115.3, "show_label": true, "label_y": 105.3}, {"at": "2026-08-14T23:59:59.999Z", "date": "2026-08-14", "label": "14 Aug 2026", "score": 55, "tone": "neutral", "raw_score": 59, "confidence": 42, "stories": 87, "close": 17.63, "price_change": 1.0, "x": 739.4, "y": 120.8, "show_label": false, "label_y": 110.8}, {"at": "2026-08-07T23:59:59.999Z", "date": "2026-08-07", "label": "07 Aug 2026", "score": 60, "tone": "positive", "raw_score": 66, "confidence": 45, "stories": 61, "close": 17.45, "price_change": 2.1, "x": 703.0, "y": 111.6, "show_label": false, "label_y": 101.6}], "reconstructed": true, "latest_close": 18.86, "price_observations": 26, "sentiment_observations": 26, "sentiment_start_label": "03 Apr 2026", "sentiment_end_label": "25 Sep 2026", "sentiment_history_limited": false, "price_axis_high": 103.0, "price_axis_mid": 92.1, "price_axis_low": 81.1, "start_label": "03 Apr", "mid_label": "30 Jun", "end_label": "25 Sep", "live_score_version": "evidence-v10", "comparable_to_live": true}, "sentiment_history": [{"label": "18 Jul 23:59", "short_label": "18 Jul", "collected_at": "2026-07-18T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": null, "score_change_display": "Start", "confidence_change": null, "article_change": null, "tone": "neutral", "height": 4, "articles": 24, "confidence": 38, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "19 Jul 23:59", "short_label": "19 Jul", "collected_at": "2026-07-19T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": -1, "score_change_display": "-1", "confidence_change": -3, "article_change": 1, "tone": "neutral", "height": 4, "articles": 25, "confidence": 35, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "20 Jul 23:59", "short_label": "20 Jul", "collected_at": "2026-07-20T23:59:59.999999+00:00", "score": 53, "delta": 3, "score_change": 2, "score_change_display": "+2", "confidence_change": 2, "article_change": 3, "tone": "neutral", "height": 6, "articles": 28, "confidence": 37, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "21 Jul 23:59", "short_label": "21 Jul", "collected_at": "2026-07-21T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": -1, "score_change_display": "-1", "confidence_change": -3, "article_change": 1, "tone": "neutral", "height": 4, "articles": 29, "confidence": 34, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "23 Jul 23:59", "short_label": "23 Jul", "collected_at": "2026-07-23T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": 2, "score_change_display": "+2", "confidence_change": 0, "article_change": 0, "tone": "neutral", "height": 8, "articles": 29, "confidence": 34, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "24 Jul 23:59", "short_label": "24 Jul", "collected_at": "2026-07-24T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": -2, "score_change_display": "-2", "confidence_change": 0, "article_change": 2, "tone": "neutral", "height": 4, "articles": 31, "confidence": 34, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "25 Jul 23:59", "short_label": "25 Jul", "collected_at": "2026-07-25T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 3, "tone": "neutral", "height": 4, "articles": 34, "confidence": 34, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "26 Jul 23:59", "short_label": "26 Jul", "collected_at": "2026-07-26T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 0, "tone": "neutral", "height": 4, "articles": 34, "confidence": 34, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "27 Jul 23:59", "short_label": "27 Jul", "collected_at": "2026-07-27T23:59:59.999999+00:00", "score": 53, "delta": 3, "score_change": 1, "score_change_display": "+1", "confidence_change": 2, "article_change": 4, "tone": "neutral", "height": 6, "articles": 38, "confidence": 36, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "28 Jul 23:59", "short_label": "28 Jul", "collected_at": "2026-07-28T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": 2, "score_change_display": "+2", "confidence_change": 2, "article_change": 3, "tone": "neutral", "height": 10, "articles": 41, "confidence": 38, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "29 Jul 23:59", "short_label": "29 Jul", "collected_at": "2026-07-29T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": -1, "score_change_display": "-1", "confidence_change": -3, "article_change": 0, "tone": "neutral", "height": 8, "articles": 41, "confidence": 35, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "30 Jul 23:59", "short_label": "30 Jul", "collected_at": "2026-07-30T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": 0, "score_change_display": "+0", "confidence_change": 2, "article_change": 7, "tone": "neutral", "height": 8, "articles": 48, "confidence": 37, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "31 Jul 23:59", "short_label": "31 Jul", "collected_at": "2026-07-31T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": 0, "score_change_display": "+0", "confidence_change": 2, "article_change": 3, "tone": "neutral", "height": 8, "articles": 51, "confidence": 39, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "02 Aug 23:59", "short_label": "02 Aug", "collected_at": "2026-08-02T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": 0, "score_change_display": "+0", "confidence_change": -5, "article_change": 0, "tone": "neutral", "height": 8, "articles": 51, "confidence": 34, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "05 Aug 23:59", "short_label": "05 Aug", "collected_at": "2026-08-05T23:59:59.999999+00:00", "score": 57, "delta": 7, "score_change": 3, "score_change_display": "+3", "confidence_change": 4, "article_change": 2, "tone": "neutral", "height": 14, "articles": 53, "confidence": 38, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "06 Aug 23:59", "short_label": "06 Aug", "collected_at": "2026-08-06T23:59:59.999999+00:00", "score": 59, "delta": 9, "score_change": 2, "score_change_display": "+2", "confidence_change": 6, "article_change": 6, "tone": "positive", "height": 18, "articles": 59, "confidence": 44, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "07 Aug 23:59", "short_label": "07 Aug", "collected_at": "2026-08-07T23:59:59.999999+00:00", "score": 60, "delta": 10, "score_change": 1, "score_change_display": "+1", "confidence_change": 1, "article_change": 2, "tone": "positive", "height": 20, "articles": 61, "confidence": 45, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "08 Aug 23:59", "short_label": "08 Aug", "collected_at": "2026-08-08T23:59:59.999999+00:00", "score": 63, "delta": 13, "score_change": 3, "score_change_display": "+3", "confidence_change": 4, "article_change": 3, "tone": "positive", "height": 26, "articles": 64, "confidence": 49, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "09 Aug 23:59", "short_label": "09 Aug", "collected_at": "2026-08-09T23:59:59.999999+00:00", "score": 62, "delta": 12, "score_change": -1, "score_change_display": "-1", "confidence_change": -4, "article_change": 1, "tone": "positive", "height": 24, "articles": 65, "confidence": 45, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "10 Aug 23:59", "short_label": "10 Aug", "collected_at": "2026-08-10T23:59:59.999999+00:00", "score": 62, "delta": 12, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": 3, "tone": "positive", "height": 24, "articles": 68, "confidence": 42, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "11 Aug 23:59", "short_label": "11 Aug", "collected_at": "2026-08-11T23:59:59.999999+00:00", "score": 61, "delta": 11, "score_change": -1, "score_change_display": "-1", "confidence_change": 0, "article_change": 3, "tone": "positive", "height": 22, "articles": 71, "confidence": 42, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "12 Aug 23:59", "short_label": "12 Aug", "collected_at": "2026-08-12T23:59:59.999999+00:00", "score": 60, "delta": 10, "score_change": -1, "score_change_display": "-1", "confidence_change": -1, "article_change": 3, "tone": "positive", "height": 20, "articles": 74, "confidence": 41, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "13 Aug 23:59", "short_label": "13 Aug", "collected_at": "2026-08-13T23:59:59.999999+00:00", "score": 56, "delta": 6, "score_change": -4, "score_change_display": "-4", "confidence_change": 4, "article_change": 12, "tone": "neutral", "height": 12, "articles": 86, "confidence": 45, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "14 Aug 23:59", "short_label": "14 Aug", "collected_at": "2026-08-14T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": -1, "score_change_display": "-1", "confidence_change": -3, "article_change": 1, "tone": "neutral", "height": 10, "articles": 87, "confidence": 42, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "15 Aug 23:59", "short_label": "15 Aug", "collected_at": "2026-08-15T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": 0, "score_change_display": "+0", "confidence_change": -4, "article_change": -1, "tone": "neutral", "height": 10, "articles": 86, "confidence": 38, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "17 Aug 23:59", "short_label": "17 Aug", "collected_at": "2026-08-17T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": 0, "score_change_display": "+0", "confidence_change": -5, "article_change": -4, "tone": "neutral", "height": 10, "articles": 82, "confidence": 33, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "18 Aug 23:59", "short_label": "18 Aug", "collected_at": "2026-08-18T23:59:59.999999+00:00", "score": 61, "delta": 11, "score_change": 6, "score_change_display": "+6", "confidence_change": 7, "article_change": 2, "tone": "positive", "height": 22, "articles": 84, "confidence": 40, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "19 Aug 23:59", "short_label": "19 Aug", "collected_at": "2026-08-19T23:59:59.999999+00:00", "score": 60, "delta": 10, "score_change": -1, "score_change_display": "-1", "confidence_change": 3, "article_change": 2, "tone": "positive", "height": 20, "articles": 86, "confidence": 43, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "20 Aug 23:59", "short_label": "20 Aug", "collected_at": "2026-08-20T23:59:59.999999+00:00", "score": 60, "delta": 10, "score_change": 0, "score_change_display": "+0", "confidence_change": -4, "article_change": 0, "tone": "positive", "height": 20, "articles": 86, "confidence": 39, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "21 Aug 23:59", "short_label": "21 Aug", "collected_at": "2026-08-21T23:59:59.999999+00:00", "score": 58, "delta": 8, "score_change": -2, "score_change_display": "-2", "confidence_change": 2, "article_change": 4, "tone": "positive", "height": 16, "articles": 90, "confidence": 41, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "24 Aug 23:59", "short_label": "24 Aug", "collected_at": "2026-08-24T23:59:59.999999+00:00", "score": 59, "delta": 9, "score_change": 1, "score_change_display": "+1", "confidence_change": 2, "article_change": -8, "tone": "positive", "height": 18, "articles": 82, "confidence": 43, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "25 Aug 23:59", "short_label": "25 Aug", "collected_at": "2026-08-25T23:59:59.999999+00:00", "score": 60, "delta": 10, "score_change": 1, "score_change_display": "+1", "confidence_change": -1, "article_change": 0, "tone": "positive", "height": 20, "articles": 82, "confidence": 42, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "28 Aug 23:59", "short_label": "28 Aug", "collected_at": "2026-08-28T23:59:59.999999+00:00", "score": 58, "delta": 8, "score_change": -2, "score_change_display": "-2", "confidence_change": -2, "article_change": -6, "tone": "positive", "height": 16, "articles": 76, "confidence": 40, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "31 Aug 23:59", "short_label": "31 Aug", "collected_at": "2026-08-31T23:59:59.999999+00:00", "score": 59, "delta": 9, "score_change": 1, "score_change_display": "+1", "confidence_change": 1, "article_change": -6, "tone": "positive", "height": 18, "articles": 70, "confidence": 41, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "01 Sep 23:59", "short_label": "01 Sep", "collected_at": "2026-09-01T23:59:59.999999+00:00", "score": 59, "delta": 9, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 0, "tone": "positive", "height": 18, "articles": 70, "confidence": 41, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "02 Sep 23:59", "short_label": "02 Sep", "collected_at": "2026-09-02T23:59:59.999999+00:00", "score": 58, "delta": 8, "score_change": -1, "score_change_display": "-1", "confidence_change": 0, "article_change": 3, "tone": "positive", "height": 16, "articles": 73, "confidence": 41, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "04 Sep 23:59", "short_label": "04 Sep", "collected_at": "2026-09-04T23:59:59.999999+00:00", "score": 57, "delta": 7, "score_change": -1, "score_change_display": "-1", "confidence_change": -4, "article_change": -3, "tone": "neutral", "height": 14, "articles": 70, "confidence": 37, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "07 Sep 23:59", "short_label": "07 Sep", "collected_at": "2026-09-07T23:59:59.999999+00:00", "score": 56, "delta": 6, "score_change": -1, "score_change_display": "-1", "confidence_change": -6, "article_change": -13, "tone": "neutral", "height": 12, "articles": 57, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "09 Sep 23:59", "short_label": "09 Sep", "collected_at": "2026-09-09T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": -1, "score_change_display": "-1", "confidence_change": -3, "article_change": -3, "tone": "neutral", "height": 10, "articles": 54, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "10 Sep 23:59", "short_label": "10 Sep", "collected_at": "2026-09-10T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": -1, "tone": "neutral", "height": 10, "articles": 53, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "11 Sep 23:59", "short_label": "11 Sep", "collected_at": "2026-09-11T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": -1, "score_change_display": "-1", "confidence_change": -1, "article_change": -1, "tone": "neutral", "height": 8, "articles": 52, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "14 Sep 23:59", "short_label": "14 Sep", "collected_at": "2026-09-14T23:59:59.999999+00:00", "score": 53, "delta": 3, "score_change": -1, "score_change_display": "-1", "confidence_change": -3, "article_change": -13, "tone": "neutral", "height": 6, "articles": 39, "confidence": 22, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "16 Sep 23:59", "short_label": "16 Sep", "collected_at": "2026-09-16T23:59:59.999999+00:00", "score": 53, "delta": 3, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 0, "tone": "neutral", "height": 6, "articles": 39, "confidence": 20, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "17 Sep 23:59", "short_label": "17 Sep", "collected_at": "2026-09-17T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": -1, "score_change_display": "-1", "confidence_change": 0, "article_change": -2, "tone": "neutral", "height": 4, "articles": 37, "confidence": 20, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "18 Sep 23:59", "short_label": "18 Sep", "collected_at": "2026-09-18T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": -1, "score_change_display": "-1", "confidence_change": 6, "article_change": 1, "tone": "neutral", "height": 4, "articles": 38, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "19 Sep 23:59", "short_label": "19 Sep", "collected_at": "2026-09-19T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 39, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "20 Sep 23:59", "short_label": "20 Sep", "collected_at": "2026-09-20T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": -3, "tone": "neutral", "height": 4, "articles": 36, "confidence": 23, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "21 Sep 23:59", "short_label": "21 Sep", "collected_at": "2026-09-21T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": 4, "score_change_display": "+4", "confidence_change": 8, "article_change": 1, "tone": "neutral", "height": 10, "articles": 37, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "22 Sep 23:59", "short_label": "22 Sep", "collected_at": "2026-09-22T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": 3, "tone": "neutral", "height": 10, "articles": 40, "confidence": 32, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "23 Sep 23:59", "short_label": "23 Sep", "collected_at": "2026-09-23T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": -1, "score_change_display": "-1", "confidence_change": -3, "article_change": -1, "tone": "neutral", "height": 8, "articles": 39, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "24 Sep 23:59", "short_label": "24 Sep", "collected_at": "2026-09-24T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 0, "tone": "neutral", "height": 8, "articles": 39, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "27 Sep 02:17", "short_label": "27 Sep", "collected_at": "2026-09-27T02:17:13.684294+00:00", "score": 53, "delta": 3, "score_change": -1, "score_change_display": "-1", "confidence_change": -3, "article_change": 0, "tone": "neutral", "height": 6, "articles": 39, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}], "sentiment_history_insight": {"available": true, "series_version": "evidence-v10", "live_version": "evidence-v10", "comparable_to_live": true, "reconstructed": true, "observations": 52, "span_label": "70 days", "first_score": 52, "latest_score": 53, "net_change": 1, "net_change_display": "+1", "direction": "Broadly stable", "high_score": 63, "low_score": 51, "latest_confidence": 24, "confidence_change": -14, "latest_articles": 39, "article_change": 15, "latest_label": "27 Sep 02:17", "latest_evidence_label": "Provisional", "chart_rows": [{"label": "18 Jul 23:59", "short_label": "18 Jul", "collected_at": "2026-07-18T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": null, "score_change_display": "Start", "confidence_change": null, "article_change": null, "tone": "neutral", "height": 4, "articles": 24, "confidence": 38, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 42.0, "y": 131.4}, {"label": "19 Jul 23:59", "short_label": "19 Jul", "collected_at": "2026-07-19T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": -1, "score_change_display": "-1", "confidence_change": -3, "article_change": 1, "tone": "neutral", "height": 4, "articles": 25, "confidence": 35, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 60.0, "y": 133.2}, {"label": "20 Jul 23:59", "short_label": "20 Jul", "collected_at": "2026-07-20T23:59:59.999999+00:00", "score": 53, "delta": 3, "score_change": 2, "score_change_display": "+2", "confidence_change": 2, "article_change": 3, "tone": "neutral", "height": 6, "articles": 28, "confidence": 37, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 77.9, "y": 129.5}, {"label": "21 Jul 23:59", "short_label": "21 Jul", "collected_at": "2026-07-21T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": -1, "score_change_display": "-1", "confidence_change": -3, "article_change": 1, "tone": "neutral", "height": 4, "articles": 29, "confidence": 34, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 95.9, "y": 131.4}, {"label": "23 Jul 23:59", "short_label": "23 Jul", "collected_at": "2026-07-23T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": 2, "score_change_display": "+2", "confidence_change": 0, "article_change": 0, "tone": "neutral", "height": 8, "articles": 29, "confidence": 34, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 113.8, "y": 127.7}, {"label": "24 Jul 23:59", "short_label": "24 Jul", "collected_at": "2026-07-24T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": -2, "score_change_display": "-2", "confidence_change": 0, "article_change": 2, "tone": "neutral", "height": 4, "articles": 31, "confidence": 34, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 131.8, "y": 131.4}, {"label": "25 Jul 23:59", "short_label": "25 Jul", "collected_at": "2026-07-25T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 3, "tone": "neutral", "height": 4, "articles": 34, "confidence": 34, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 149.8, "y": 131.4}, {"label": "26 Jul 23:59", "short_label": "26 Jul", "collected_at": "2026-07-26T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 0, "tone": "neutral", "height": 4, "articles": 34, "confidence": 34, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 167.7, "y": 131.4}, {"label": "27 Jul 23:59", "short_label": "27 Jul", "collected_at": "2026-07-27T23:59:59.999999+00:00", "score": 53, "delta": 3, "score_change": 1, "score_change_display": "+1", "confidence_change": 2, "article_change": 4, "tone": "neutral", "height": 6, "articles": 38, "confidence": 36, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 185.7, "y": 129.5}, {"label": "28 Jul 23:59", "short_label": "28 Jul", "collected_at": "2026-07-28T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": 2, "score_change_display": "+2", "confidence_change": 2, "article_change": 3, "tone": "neutral", "height": 10, "articles": 41, "confidence": 38, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 203.6, "y": 125.9}, {"label": "29 Jul 23:59", "short_label": "29 Jul", "collected_at": "2026-07-29T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": -1, "score_change_display": "-1", "confidence_change": -3, "article_change": 0, "tone": "neutral", "height": 8, "articles": 41, "confidence": 35, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 221.6, "y": 127.7}, {"label": "30 Jul 23:59", "short_label": "30 Jul", "collected_at": "2026-07-30T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": 0, "score_change_display": "+0", "confidence_change": 2, "article_change": 7, "tone": "neutral", "height": 8, "articles": 48, "confidence": 37, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 239.6, "y": 127.7}, {"label": "31 Jul 23:59", "short_label": "31 Jul", "collected_at": "2026-07-31T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": 0, "score_change_display": "+0", "confidence_change": 2, "article_change": 3, "tone": "neutral", "height": 8, "articles": 51, "confidence": 39, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 257.5, "y": 127.7}, {"label": "02 Aug 23:59", "short_label": "02 Aug", "collected_at": "2026-08-02T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": 0, "score_change_display": "+0", "confidence_change": -5, "article_change": 0, "tone": "neutral", "height": 8, "articles": 51, "confidence": 34, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 275.5, "y": 127.7}, {"label": "05 Aug 23:59", "short_label": "05 Aug", "collected_at": "2026-08-05T23:59:59.999999+00:00", "score": 57, "delta": 7, "score_change": 3, "score_change_display": "+3", "confidence_change": 4, "article_change": 2, "tone": "neutral", "height": 14, "articles": 53, "confidence": 38, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 293.5, "y": 122.3}, {"label": "06 Aug 23:59", "short_label": "06 Aug", "collected_at": "2026-08-06T23:59:59.999999+00:00", "score": 59, "delta": 9, "score_change": 2, "score_change_display": "+2", "confidence_change": 6, "article_change": 6, "tone": "positive", "height": 18, "articles": 59, "confidence": 44, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 311.4, "y": 118.6}, {"label": "07 Aug 23:59", "short_label": "07 Aug", "collected_at": "2026-08-07T23:59:59.999999+00:00", "score": 60, "delta": 10, "score_change": 1, "score_change_display": "+1", "confidence_change": 1, "article_change": 2, "tone": "positive", "height": 20, "articles": 61, "confidence": 45, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 329.4, "y": 116.8}, {"label": "08 Aug 23:59", "short_label": "08 Aug", "collected_at": "2026-08-08T23:59:59.999999+00:00", "score": 63, "delta": 13, "score_change": 3, "score_change_display": "+3", "confidence_change": 4, "article_change": 3, "tone": "positive", "height": 26, "articles": 64, "confidence": 49, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 347.3, "y": 111.3}, {"label": "09 Aug 23:59", "short_label": "09 Aug", "collected_at": "2026-08-09T23:59:59.999999+00:00", "score": 62, "delta": 12, "score_change": -1, "score_change_display": "-1", "confidence_change": -4, "article_change": 1, "tone": "positive", "height": 24, "articles": 65, "confidence": 45, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 365.3, "y": 113.2}, {"label": "10 Aug 23:59", "short_label": "10 Aug", "collected_at": "2026-08-10T23:59:59.999999+00:00", "score": 62, "delta": 12, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": 3, "tone": "positive", "height": 24, "articles": 68, "confidence": 42, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 383.3, "y": 113.2}, {"label": "11 Aug 23:59", "short_label": "11 Aug", "collected_at": "2026-08-11T23:59:59.999999+00:00", "score": 61, "delta": 11, "score_change": -1, "score_change_display": "-1", "confidence_change": 0, "article_change": 3, "tone": "positive", "height": 22, "articles": 71, "confidence": 42, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 401.2, "y": 115.0}, {"label": "12 Aug 23:59", "short_label": "12 Aug", "collected_at": "2026-08-12T23:59:59.999999+00:00", "score": 60, "delta": 10, "score_change": -1, "score_change_display": "-1", "confidence_change": -1, "article_change": 3, "tone": "positive", "height": 20, "articles": 74, "confidence": 41, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 419.2, "y": 116.8}, {"label": "13 Aug 23:59", "short_label": "13 Aug", "collected_at": "2026-08-13T23:59:59.999999+00:00", "score": 56, "delta": 6, "score_change": -4, "score_change_display": "-4", "confidence_change": 4, "article_change": 12, "tone": "neutral", "height": 12, "articles": 86, "confidence": 45, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 437.1, "y": 124.1}, {"label": "14 Aug 23:59", "short_label": "14 Aug", "collected_at": "2026-08-14T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": -1, "score_change_display": "-1", "confidence_change": -3, "article_change": 1, "tone": "neutral", "height": 10, "articles": 87, "confidence": 42, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 455.1, "y": 125.9}, {"label": "15 Aug 23:59", "short_label": "15 Aug", "collected_at": "2026-08-15T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": 0, "score_change_display": "+0", "confidence_change": -4, "article_change": -1, "tone": "neutral", "height": 10, "articles": 86, "confidence": 38, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 473.1, "y": 125.9}, {"label": "17 Aug 23:59", "short_label": "17 Aug", "collected_at": "2026-08-17T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": 0, "score_change_display": "+0", "confidence_change": -5, "article_change": -4, "tone": "neutral", "height": 10, "articles": 82, "confidence": 33, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 491.0, "y": 125.9}, {"label": "18 Aug 23:59", "short_label": "18 Aug", "collected_at": "2026-08-18T23:59:59.999999+00:00", "score": 61, "delta": 11, "score_change": 6, "score_change_display": "+6", "confidence_change": 7, "article_change": 2, "tone": "positive", "height": 22, "articles": 84, "confidence": 40, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 509.0, "y": 115.0}, {"label": "19 Aug 23:59", "short_label": "19 Aug", "collected_at": "2026-08-19T23:59:59.999999+00:00", "score": 60, "delta": 10, "score_change": -1, "score_change_display": "-1", "confidence_change": 3, "article_change": 2, "tone": "positive", "height": 20, "articles": 86, "confidence": 43, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 526.9, "y": 116.8}, {"label": "20 Aug 23:59", "short_label": "20 Aug", "collected_at": "2026-08-20T23:59:59.999999+00:00", "score": 60, "delta": 10, "score_change": 0, "score_change_display": "+0", "confidence_change": -4, "article_change": 0, "tone": "positive", "height": 20, "articles": 86, "confidence": 39, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 544.9, "y": 116.8}, {"label": "21 Aug 23:59", "short_label": "21 Aug", "collected_at": "2026-08-21T23:59:59.999999+00:00", "score": 58, "delta": 8, "score_change": -2, "score_change_display": "-2", "confidence_change": 2, "article_change": 4, "tone": "positive", "height": 16, "articles": 90, "confidence": 41, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 562.9, "y": 120.4}, {"label": "24 Aug 23:59", "short_label": "24 Aug", "collected_at": "2026-08-24T23:59:59.999999+00:00", "score": 59, "delta": 9, "score_change": 1, "score_change_display": "+1", "confidence_change": 2, "article_change": -8, "tone": "positive", "height": 18, "articles": 82, "confidence": 43, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 580.8, "y": 118.6}, {"label": "25 Aug 23:59", "short_label": "25 Aug", "collected_at": "2026-08-25T23:59:59.999999+00:00", "score": 60, "delta": 10, "score_change": 1, "score_change_display": "+1", "confidence_change": -1, "article_change": 0, "tone": "positive", "height": 20, "articles": 82, "confidence": 42, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 598.8, "y": 116.8}, {"label": "28 Aug 23:59", "short_label": "28 Aug", "collected_at": "2026-08-28T23:59:59.999999+00:00", "score": 58, "delta": 8, "score_change": -2, "score_change_display": "-2", "confidence_change": -2, "article_change": -6, "tone": "positive", "height": 16, "articles": 76, "confidence": 40, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 616.7, "y": 120.4}, {"label": "31 Aug 23:59", "short_label": "31 Aug", "collected_at": "2026-08-31T23:59:59.999999+00:00", "score": 59, "delta": 9, "score_change": 1, "score_change_display": "+1", "confidence_change": 1, "article_change": -6, "tone": "positive", "height": 18, "articles": 70, "confidence": 41, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 634.7, "y": 118.6}, {"label": "01 Sep 23:59", "short_label": "01 Sep", "collected_at": "2026-09-01T23:59:59.999999+00:00", "score": 59, "delta": 9, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 0, "tone": "positive", "height": 18, "articles": 70, "confidence": 41, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 652.7, "y": 118.6}, {"label": "02 Sep 23:59", "short_label": "02 Sep", "collected_at": "2026-09-02T23:59:59.999999+00:00", "score": 58, "delta": 8, "score_change": -1, "score_change_display": "-1", "confidence_change": 0, "article_change": 3, "tone": "positive", "height": 16, "articles": 73, "confidence": 41, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 670.6, "y": 120.4}, {"label": "04 Sep 23:59", "short_label": "04 Sep", "collected_at": "2026-09-04T23:59:59.999999+00:00", "score": 57, "delta": 7, "score_change": -1, "score_change_display": "-1", "confidence_change": -4, "article_change": -3, "tone": "neutral", "height": 14, "articles": 70, "confidence": 37, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 688.6, "y": 122.3}, {"label": "07 Sep 23:59", "short_label": "07 Sep", "collected_at": "2026-09-07T23:59:59.999999+00:00", "score": 56, "delta": 6, "score_change": -1, "score_change_display": "-1", "confidence_change": -6, "article_change": -13, "tone": "neutral", "height": 12, "articles": 57, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 706.5, "y": 124.1}, {"label": "09 Sep 23:59", "short_label": "09 Sep", "collected_at": "2026-09-09T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": -1, "score_change_display": "-1", "confidence_change": -3, "article_change": -3, "tone": "neutral", "height": 10, "articles": 54, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 724.5, "y": 125.9}, {"label": "10 Sep 23:59", "short_label": "10 Sep", "collected_at": "2026-09-10T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": -1, "tone": "neutral", "height": 10, "articles": 53, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 742.5, "y": 125.9}, {"label": "11 Sep 23:59", "short_label": "11 Sep", "collected_at": "2026-09-11T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": -1, "score_change_display": "-1", "confidence_change": -1, "article_change": -1, "tone": "neutral", "height": 8, "articles": 52, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 760.4, "y": 127.7}, {"label": "14 Sep 23:59", "short_label": "14 Sep", "collected_at": "2026-09-14T23:59:59.999999+00:00", "score": 53, "delta": 3, "score_change": -1, "score_change_display": "-1", "confidence_change": -3, "article_change": -13, "tone": "neutral", "height": 6, "articles": 39, "confidence": 22, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 778.4, "y": 129.5}, {"label": "16 Sep 23:59", "short_label": "16 Sep", "collected_at": "2026-09-16T23:59:59.999999+00:00", "score": 53, "delta": 3, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 0, "tone": "neutral", "height": 6, "articles": 39, "confidence": 20, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 796.4, "y": 129.5}, {"label": "17 Sep 23:59", "short_label": "17 Sep", "collected_at": "2026-09-17T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": -1, "score_change_display": "-1", "confidence_change": 0, "article_change": -2, "tone": "neutral", "height": 4, "articles": 37, "confidence": 20, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 814.3, "y": 131.4}, {"label": "18 Sep 23:59", "short_label": "18 Sep", "collected_at": "2026-09-18T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": -1, "score_change_display": "-1", "confidence_change": 6, "article_change": 1, "tone": "neutral", "height": 4, "articles": 38, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 832.3, "y": 133.2}, {"label": "19 Sep 23:59", "short_label": "19 Sep", "collected_at": "2026-09-19T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 39, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 850.2, "y": 133.2}, {"label": "20 Sep 23:59", "short_label": "20 Sep", "collected_at": "2026-09-20T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": -3, "tone": "neutral", "height": 4, "articles": 36, "confidence": 23, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 868.2, "y": 133.2}, {"label": "21 Sep 23:59", "short_label": "21 Sep", "collected_at": "2026-09-21T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": 4, "score_change_display": "+4", "confidence_change": 8, "article_change": 1, "tone": "neutral", "height": 10, "articles": 37, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 886.2, "y": 125.9}, {"label": "22 Sep 23:59", "short_label": "22 Sep", "collected_at": "2026-09-22T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": 3, "tone": "neutral", "height": 10, "articles": 40, "confidence": 32, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 904.1, "y": 125.9}, {"label": "23 Sep 23:59", "short_label": "23 Sep", "collected_at": "2026-09-23T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": -1, "score_change_display": "-1", "confidence_change": -3, "article_change": -1, "tone": "neutral", "height": 8, "articles": 39, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 922.1, "y": 127.7}, {"label": "24 Sep 23:59", "short_label": "24 Sep", "collected_at": "2026-09-24T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 0, "tone": "neutral", "height": 8, "articles": 39, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 940.0, "y": 127.7}, {"label": "27 Sep 02:17", "short_label": "27 Sep", "collected_at": "2026-09-27T02:17:13.684294+00:00", "score": 53, "delta": 3, "score_change": -1, "score_change_display": "-1", "confidence_change": -3, "article_change": 0, "tone": "neutral", "height": 6, "articles": 39, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 958.0, "y": 129.5}], "chart_points": "42.0,131.4 60.0,133.2 77.9,129.5 95.9,131.4 113.8,127.7 131.8,131.4 149.8,131.4 167.7,131.4 185.7,129.5 203.6,125.9 221.6,127.7 239.6,127.7 257.5,127.7 275.5,127.7 293.5,122.3 311.4,118.6 329.4,116.8 347.3,111.3 365.3,113.2 383.3,113.2 401.2,115.0 419.2,116.8 437.1,124.1 455.1,125.9 473.1,125.9 491.0,125.9 509.0,115.0 526.9,116.8 544.9,116.8 562.9,120.4 580.8,118.6 598.8,116.8 616.7,120.4 634.7,118.6 652.7,118.6 670.6,120.4 688.6,122.3 706.5,124.1 724.5,125.9 742.5,125.9 760.4,127.7 778.4,129.5 796.4,129.5 814.3,131.4 832.3,133.2 850.2,133.2 868.2,133.2 886.2,125.9 904.1,125.9 922.1,127.7 940.0,127.7 958.0,129.5", "changes": [{"label": "27 Sep 02:17", "short_label": "27 Sep", "collected_at": "2026-09-27T02:17:13.684294+00:00", "score": 53, "delta": 3, "score_change": -1, "score_change_display": "-1", "confidence_change": -3, "article_change": 0, "tone": "neutral", "height": 6, "articles": 39, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "24 Sep 23:59", "short_label": "24 Sep", "collected_at": "2026-09-24T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 0, "tone": "neutral", "height": 8, "articles": 39, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "23 Sep 23:59", "short_label": "23 Sep", "collected_at": "2026-09-23T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": -1, "score_change_display": "-1", "confidence_change": -3, "article_change": -1, "tone": "neutral", "height": 8, "articles": 39, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "22 Sep 23:59", "short_label": "22 Sep", "collected_at": "2026-09-22T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": 3, "tone": "neutral", "height": 10, "articles": 40, "confidence": 32, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "21 Sep 23:59", "short_label": "21 Sep", "collected_at": "2026-09-21T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": 4, "score_change_display": "+4", "confidence_change": 8, "article_change": 1, "tone": "neutral", "height": 10, "articles": 37, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "20 Sep 23:59", "short_label": "20 Sep", "collected_at": "2026-09-20T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": -3, "tone": "neutral", "height": 4, "articles": 36, "confidence": 23, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "19 Sep 23:59", "short_label": "19 Sep", "collected_at": "2026-09-19T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 39, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "18 Sep 23:59", "short_label": "18 Sep", "collected_at": "2026-09-18T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": -1, "score_change_display": "-1", "confidence_change": 6, "article_change": 1, "tone": "neutral", "height": 4, "articles": 38, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}]}, "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}